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Glioblastoma (GBM) is one of the most deadly forms of cancer with a mean 5-year survival rate 
of ≤5%. We have used the non-invasive strategy of long-term intranasal (IN) delivery of a 
glioblastoma-directed adduct of curcumin (CC), CC-CD68Ab, into the brain of murine GBM cell 
line GL261-implanted mice to study the therapeutic effect of CC on GBM remission. The 
treatment caused GBM tumor remission in 50% of GL261-implanted GBM mice. A similar 
rescue rate (60%) was also achieved through long-term intraperitoneal (i.p) infusion of a highly 
bioavailable phosphotidylcholine (PC)-encapsulated formulation of CC, Curcumin Phytosome 
Meriva (CCP), into the GL261-implanted GBM mice. However, it has been reported that 
systemic application of CCP yields only sub-IC50 concentrations of CC in the plasma, which is 
not likely to kill GBM cells directly.  Exploring the oncoimunotherapeutic potential of CC on the 
tumor microenvironment, we found a striking CCP- and CC-CD68Ab-evoked alteration in the 
activation phenotype of the Iba1(+) tumor-associated microglia/macrophages (TAM).  This 









 M2-like TAM along with a concomitant, dramatic expansion 
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 M1-like TAM. Simultaneously, we 
observed a sharp inhibition of activated STAT3 and induction of both activated STAT1 and 
activated p65 NF-kB in the TAM. TAM-associated activated p65 NF-kB and activated STAT1 
are known to synergistically cause the observed expression of iNOS and IL12.  Therefore, our 
novel findings indicate that appropriately delivered CC most likely kills GBM cells via 
repolarization of the M2-like TAMs to the tumoricidal M1-like phenotype. Additionally, we also 
observed that long-term CC evoked intra-GBM recruitment of tumoricidal activated natural 
killer (NK) cells. Since NK cells are known to boost the M1-like phenotype of TAM, we further 
investigated the function of these NK cells in the repolarization of TAM and in the elimination of 
GBM and GBM stem cells. To this end, a short-term CCP treatment (five days) caused the GBM 
tumor to acquire a large number of M1-type macrophages (50-60% of the TAM) and activated 
NK cells.  The treatment also elicited (a) suppression of the M2-like TAM-associated tumor-
promoting proteins STAT3, ARG1, and IL10, (b) induction of the M1-like TAM-associated anti-
tumor proteins STAT1, iNOS and IL12, (c) elimination of CD133(+) and SOX2(+) GBM stem 
cells, and (d) activation of caspase3 (apoptosis) in the GBM cells. Eliminating intra-GBM NK 
cell recruitment and abrogating IL12-mediated NK cell activation and recruitment caused a 
partial reversal of each of all of these effects. Concomitantly, we observed a CCP-induced potent 
induction of the chemokine monocyte chemotactic protein-1 (MCP-1) in the TAM.  Thus, our 
results demonstrate that the recruited NK cells mediate a major part of the CCP-evoked 
elimination of GBM and GBM stem cells and cause stabilization of the M1-like phenotype of the 
TAM. MCP-1 is known to compromise the blood-brain barrier, exit the brain, and activate 
peripheral M1-type macrophages which in turn are known to activate NK cells. Based on these 
observations, we postulate that by binding to peripheral M1-type macrophages and IL12-
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activated NK cells, the chemokine MCP-1 produced by the GBM-associated M1-like microglia 
causes recruitment of peripheral immune cells into the GBM to cause elimination of the GBM 









I dedicate this thesis to my mother, father, loving wife, my 
grandparents, friends and teachers who have helped me grow and 
improve as a person with their unconditional love, support, 




 I am eternally indebted to all the members of the Biochemistry doctoral 
program at the City University of New York Graduate Center and to the wonderful 
people of the Center for Developmental Neuroscience and the Chemistry 
department of the College of Staten Island for their support, encouragement, 
collaborations and ideas. I would like to express my sincerest gratitude to my 
mentor, Dr. Probal Banerjee for his constructive supervision these last six years. 
He has been selfless with his time, knowledge and ideas. I would also like to 
express my sincere gratefulness to the members of my doctoral committee 
members Dr. Raja, Dr. Junaid, Dr. Kashfi and Dr. Symons for kindly giving their 
time, guidance, and advice. Special thanks to Dr. Zhou, Dr. Fata, Dr. Pan and Dr. 
Yang for giving me the opportunity to collaborate with them. My special thanks to 
the members of Dr. Banerjee’s lab, former and current. Without the members of 
my team this thesis would not have been possible. Special thanks to Juliet Baidoo, 
Angela Fried, Rahman Hussaini and Richard White. I also want to thank 
Alexandra and Tatyana from our lab both of whom have been invaluable friends to 
me throughout my PhD journey. 
 Finally, I want to thank my parents, my loving wife Kaushiki, uncles, aunts 
and grandparents. It was the faith of my family members in me which inspired me 
to work harder to achieve my dreams. 
ix 
 
Table of Contents:          
             page 
Chapter 1: Introduction...... ......................................................1 
 1.1  Glioblastoma brain tumor.......................................................................................................1
 1.2  Curcumin and its potentiated forms as effective tumoricidal agents................................. 2 
 1.3  Curcumin: A potential oncoimmunotherapeutic agent in GBM therapy..........................4  
 1.4  Involvement of the Brain’s Innate Immune System in Curcumin-Mediated Elimination 
 of  GBM: Investigating the Role of Tumor-Associated Microglia/Macrophage.......................4 
 1.5  Role of Intra-tumor NK cell recruitment in Enhancing the M1-phenotype of the TAMs 
 Upon CCP Treatment.....................................................................................................................5 
 
Chapter 2: Methods and materials ...........................................8 
 2.1  Cell culture of human, murine and patient-derived GBM cells..........................................8 
 2.2  Generation of glioblastoma patient-derived lines GBM6, GBM46, GBM994 from three 
 different glioblastoma patients......................................................................................................8 
 2.3  Animals.....................................................................................................................................9 
 2.4  Immunocytochemistry.............................................................................................................9 
 2.5  Research design......................................................................................................................10 
 2.6  Implantation of cancer cells in mice.....................................................................................10 
 2.7  Preparation of Dylight 800-CD68Ab and curcumin-CD68Ab adducts............................11 
 2.8  Curcumin Phytosome Meriva (CCP)...................................................................................12 
 2.9  Drug treatments and determination of IC50.......................................................................12 
x 
 
 2.10  Intranasal delivery of the Dylight 800-CD68Ab and the CC-CD68Ab adduct..............13 
             2.11  Intra-peritoneal delivery of CCP on GL261 implanted mice......................................... 14 
 2.12  Post-mortem brain examination by ex vivo near-IR scanning and post-mortem 
 determination of GBM Tumor load............................................................................................14 
 2.13  Immunohistochemistry of brain tumors and scar tissue region......................................15 
 2.14  Flow cytometry of immunostained brain tumor and scar tissue cells.............................17 
 2.15  Hematoxylin and eosin (H&E) staining of brain sections................................................19 
 2.16  Neutralization of NK cells by intra-peritoneal infusion of NK1.1 Ab.............................19 
 2.17  Neutralization of IL12-mediated signaling in NK cells by intra-peritoneal infusion of 
 IL12 Ab..........................................................................................................................................19 
 2.18  Statistical analysis:...............................................................................................................20 
 
Chapter 3: Results....................................................................21 
 3.1  Mouse glioblastoma (GL261) cells, human glioblastoma (U87MG) cells, and patient-
 derived GBM explants (GBM6, GBM46 and GBM994) express high levels of CD68 
 ........................................................................................................................................................21 
 3.2 Vehicle-treated, GL261-evoked established GBM tumor cells showed strong CD68 
 expression, while the TAM were of microglial origin being CD68
low
, Iba1(+) (marks both 
 activated microglia and macrophage) but RM0029-11H3- (macrophage specific marker) 
 ........................................................................................................................................................23  
 3.3  Attachment of CC to CD68 antibody causes a dramatic enhancement of CC's cytotoxic 
 potency on GBM cells in vitro:....................................................................................................24  
 3.4  Curcumin Phytosome (CCP) eliminates GBM cells in culture with similar potency as 
 free curcumin:..............................................................................................................................27 
xi 
 
 3.5  Both intranasal delivery of CC-CD68Ab adduct and peripheral CCP treatment were 
 effective in causing elimination GL261-evoked GBM tumor and rescue of mice...................29 
 3.6  Curcumin treatment and rescue is associated with a dramatic shift in the relative 
 expression profiles of ARG1 and iNOS in Iba1(+) TAM..........................................................34 
 3.7  Flow cytometry analysis in GBM or scar tissue indicates that discrete populations of 
 Iba1(+) TAM are affected during CC-treatment and rescue....................................................36 
 3.8  CC-treated and rescue of GBM mice was associated with a pronounced inhibition of 
 activated-STAT3 and IL10, and dramatic induction of activated-NF-kB (p65), activated-
 STAT1 and IL12 in the TAM......................................................................................................38  
 3.9  CCP treatment-associated recruitment of activated NK cells into the GBM tumor 
 ........................................................................................................................................................43  
 3.10  GL261 implantation on day 1 results in a large brain tumors on day 17, which harbors 
 CD68
high
, Iba1(-) tumor cells and CD68
low
, Iba1(+) TAM........................................................ 46  
 3.11  CCP treatment triggers NK cell recruitment into the GBM tumor and peripheral 
 NK1.1Ab pre-treatment abrogates it........................................................................................  47 
 3.12  Intra-GBM recruitment of NK cells is eliminated upon neutralization of peripheral 
 IL12 signaling using an IL12 antibody...................................................................................... 50   
 3.13  CCP treatment causes NK cell-independent recruitment of activated macrophages 
 into GBM...................................................................................................................................... 50 
 3.14  CCP treatment causes a dramatic suppression of STAT3 in TAM, which is partially 
 reversed in the NK1.1Ab-treated mice.....................................................................................   53 
 3.15  CCP treatment prompts a dramatic increase in P-STAT1, which is partially reversed 
 in the NK1.1Ab-treated mice.....................................................................................................  55  
 3.16  Pretreatment with the NK1.1Ab partially blocks the CCP-evoked M2M1 
 repolarization..............................................................................................................................  56  
 3.17  NK1.1Ab treatment partially reverses CCP-evoked elimination of CD133(+) and     
 SOX2(+) GBM stem cells and caspase-3 activation in CD68high GBM cells.........................61 
xii 
 
 3.18 In the CCP-treated GBM mice, the M1-like polarity of both macrophages and 
 microglia in the GBM tumor is partially eliminated upon peripheral injection of the IL12 
 antibody........................................................................................................................................ 66 
 3.19  3.19 CCP treatment causes a dramatic IL12-independent induction of            
 monocyte chemotactic protein-1 (MCP-1) expression in the TAM............................... 67 
  
Chapter 4: Discussion ..............................................................72 
 















List of Figures: 
Figure  
 
  Page number  
1 CD68 is highly expressed by both mouse (GL261) and human (U87MG) GBM cells in 
culture..........................................................................................................................................22  
2  Patient-derived GBM explants express CD68 ....................................................................... 22 
3 Vehicle-treated, GL261-evoked established GBM tumor cells showed strong CD68 
expression, whereas the TAM were chiefly CD68
low
 and Iba1(+) (marks both activated 
microglia and macrophages) but RM0029-11H3(-) (macrophage specific marker) 
microglia.................................................................................................................................... 24 
4 Synthesis and subsequent MALDI-TOF analysis of the CC-CD68Ab adduct ................... 26 
5 CD68 Ab-linked CC (CC-CD68Ab adduct) is 120-times more potent than free CC in 
eliminating GL261 cells in culture. ......................................................................................... 27 
6 Dose-response of targeted CC of the CC-CD68Ab adduct in patient-derived GBM 
explants.....................................................................................................................................  28 
7 Curcumin Phytosome Meriva (CCP)  eliminates GBM cells in culture with similar potency 
as free CC .................................................................................................................................  28 
8 Efficient delivery strategies for therapeutic delivery of CC-CD68Ab and CCP to GBM 
mice ...........................................................................................................................................   31 
9 H&E staining of tumor and scar tissue region ....................................................................    32 
xiv 
 
10 Absence of CD68high GBM tumor cells in the scar tissue area in the CC-treated and rescued 
mice.............................................................................................................................................. 33 
11 CC treatment and rescue is associated with a dramatic shift in the relative expression of 
ARG1 and iNOS in Iba1(+) TAM ............................................................................................35 
12 Flow cytometry analysis of Iba1(+) TAM in GBM and scar tissue regions .........................37 
13 The TAM (Iba1(+)) in the CCP-treated and rescued mice displayed a dramatic inhibition 
of activated STAT3 ..................................................................................................................  39 
14 Induced STAT1 expression and activation in Iba1(+) TAM in the scar tissue region of the 
CC-treated and rescued mice ...................................................................................................40 
15 Induced p65 NF-kB expression and activation in the Iba1(+) TAM in the scar tissue region 
of the CC-treated and rescued mice ........................................................................................ 42 
16 Iba1(+) microglia/macrophages (TAM) are IL10high and IL12low, whereas the TAM in the 





17 CCP-treatment and rescue of GBM mice is associated with the scar tissue rescued mice 
harboring activated natural killer (NK) cells .........................................................................45 
18 GBM tumor generation by GL261 implantation on day 1, peripheral treatment with mouse 
IgG (MS) or the NK-cell-neutralizing NK1.1 antibody on day 11, followed by a regimen of 




19 5-day CCP treatment is associated with intra-tumor recruitment of activated NK cells, 
which is eliminated by peripheral injection with the NK cell-neutralizing NK1.1 antibody 
(NK1.1Ab) in mice .................................................................................................................... 48 
20 Five-day CCP treatment causes intra-tumor recruitment of activated NK cells, which is 
eliminated in mice treated peripherally with an IL12 Ab .................................................... 51 
21 CCP treatment triggers NK cell-independent, intra-GBM recruitment of peripheral 
macrophages............................................................................................................................... 52 
22 The elimination of intra-GBM recruitment of activated NK cells by peripheral injection of 
NK1.1 Ab partially reverts the CCP-mediated suppression of activated STAT3 in the TAM 
.....................................................................................................................................................54 
23 Elimination of intra-GBM recruitment of activated NK cells partially reverses the CCP-
mediated induction and activation of STAT1 in the TAM.................................................... 55 
24 Peripheral injection of the GBM mice with a NK cell-neutralizing antibody NK1.1 
partially blocks the CCP-mediated-M2 to M1 repolarization of the TAM 
...................................................................................................................................................... 57 
25 Neutralization of intra-GBM recruitment of activated NK cell partially reverses the CCP-
mediated repolarization of TAM..............................................................................................59 
26 Abrogation of the intra-GBM recruitment of activated NK cell partially reverses the CCP-







The elimination of intra-GBM recruitment of activated NK cells partially reverses the 
CCP-evoked elimination of CD133(+) GBM stem cells and CD68
high
 GBM cells ............... 63 
28 Peripheral injection of the GBM mice with a NK cell-neutralizing antibody NK1.1 
partially reverses the CCP-mediated elimination of SOX2(+) GBM stem cells ...................64  
29 The abrogation of intra-GBM recruitment of activated NK cells by peripheral injection 
with IL12 Ab partially eliminated the M1-type phenotype of  the GBM TAM ...................65  
30 CCP treatment causes a dramatic induction of MCP-1 in the Iba1(+) TAM ......................69 
31 Possible signaling pathways involved in the CCP-mediated M2M1 TAM repolarization, 












2xSSC - 2x saline-sodium citrate buffer 
anti-RM0029-11H3 - Anti-Macrophage antibody 
ARG1 -Arginase1  
BBB - blood-brain barrier 
CC - Curcumin 
CC-CD68Ab - CD68 antibody linked Curcumin adduct 
CCP - Curcumin Phytosome Meriva 
CCP+IL12Ab -  IL12-Neutralizing Antibody Infusion Followed By Curcumin Phytosome 
Meriva Treatment 
CCP+NK1.1Ab/ CCP+NK1.1- Natural Killer Cell-Neutralizing Antibody Infusion 
Followed By Curcumin Phytosome Meriva Treatment 
CCR2 - chemokine receptor type 2 
CD - Cluster of Differentiation 
CSI -College of Staten Island 
CUNY -City University of New York 
DMEM - Dulbecco’s Modified Eagles Medium 
DMSO - Dimethyl sulfoxide 
Dylight800-CD68Ab - CD68 antibody linked Dylight800 dye  
GBM- Glioblastoma 
HCl - hydrochloric acid  
IACUC - Institutional Animal Care Committee 
xviii 
 
Iba1 - Ionized Calcium-Binding Adapter Molecule 1 
IF - Integrated Fluorescence 
IFNγ -Interferon-gamma 
IgG -Immunoglobulin G 
IHC -immunohistochemistry 
IL10 -Interleukin 10 
IL12 -Interleukin 12 
IL12Ab - IL12-neutralizing antibody treatment 
IL12R - IL12 receptor 
iNOS - Inducible Nitric Oxide Synthase  
ITS - Insulin transferrin selenium supplement 
LR -Lower right 
MCP-1 - Monocyte Chemotactic Protein-1 (CCL2) 
NIH- National Institute of Health 
NHS - N-hydroxysuccinimide 
NIR - Near infrared 
NK cells - Natural Killer cells 
NK1.1 Ab - Natural Killer cell-neutralizing antibody treatment 
NO - Nitric oxide 
p65 NF-kB - p65 subunit of nuclear factor-kB 
PBS -Phosphate-buffered saline 
PC - Phosphotidylcholine 
P-Tyr701-STAT1- phospho-STAT1 antbody 
xix 
 
P-Tyr705-STAT3 -phospho-STAT3 antbody 
P- Ser276-p65 NF-kB: Phospho-p65 NF-kB 
RPMI - Roswell Park Memorial Institute (medium) 
RT - Room Temparature 
STAT1/3 - Signal Transducer and Activator of Transcription 1/3 
TAM - tumor-associated microglia/macrophages  
TMZ -temozolomide  





Parts of the work presented in this thesis are included in the following peer-
reviewed published articles: 
 
1. Phyllis Langone, Priya Ranjan Debata, Joseph Del Rosario Inigo, Sukanta Dolai, Sumit 
Mukherjee, Peter Halat, Kristina Mastroianni et al. "Coupling to a glioblastoma-directed 
antibody potentiates antitumor activity of curcumin." International Journal of Cancer 135, 
no. 3 (2014): 710-719. 
 
2. Sumit Mukherjee, Juliet Baidoo, Angela Fried, Doaa Atwi, Sukanta Dolai, John Boockvar, 
Marc Symons, Rosamaria Ruggieri, Krishnaswami Raja, and Probal Banerjee (2016), 
"Curcumin changes the polarity of tumor-associated microglia and eliminates 
glioblastoma". International Journal of Cancer, 139: 2838–2849 (2016).  
 
3. Sumit Mukherjee, Angela Fried, Rahman Hussaini, Richard White, Juliet Baidoo, Sree 
Yalamachi, and Probal Banerjee. "Phytosomal Curcumin Causes Natural Killer Cell-
Dependent Repolarization of Glioblastoma (GBM) Tumor-Associated 
Microglia/Macrophages and Elimination of GBM and GBM Stem Cells" Journal of 








Chapter 1: Introduction 
1.1 Glioblastoma brain tumor. 
Glioblastoma Multiforme (GBM) is a lethal form of primary brain tumor, which mainly 
originates from carcinogenesis in the brain astrocytes and represents roughly 15% of adult 
primary brain tumor cases (1-3). Surprisingly, the highest occurrence of GBM brain tumor is 
seen in the industrially developed countries with increased incidence every year (4, 5). Although 
the causes for most GBM cases are unclear, etiological studies have linked some risk factors to 
GBM development, for example, contact with ionizing radiation, exposure to agents such as 
vinyl chloride or pesticides, habits like smoking, and occupational hazards like petroleum 
refining or production work and employment in synthetic rubber manufacturing industries (6). 
Some other studies have associated GBM formation to dietary intake of large quantities of 
processed meat and animal protein (5, 7).  
  Standard GBM therapy is mainly palliative and average survival rate of GBM patients is 
approximately 12-15 months from diagnosis, despite the currently available standard of care 
which consists of tumor debulking surgery followed by radiotherapy and/or chemotherapy to 
eradicate residual tumors (5). Subsequently, the patient undergoes a 5-day chemotherapeutic 
treatment with a high-dose of temozolomide (TMZ) (150-200 mg/m
2
/day) every 4 weeks (5, 8-
11). Unfortunately, neurotoxicity triggered by mechanical traumas from surgery, radiotherapy 
and chemotherapy can augment extracellular levels of glutamine, which induces tumor 
propagation and metastasis of GBM cells (12). Furthermore, exposure to radiotherapy can cause 
tumor resurgence by stimulating the reactivation of the GBM stem cells (13). Additionally, long-
term treatment with TMZ can evoke acute lymphopenia and immunosuppression, which are 
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known to cause further tumor proliferation and metastasis (14-20). Without treatment with the 
above mentioned standard of care, the life span of GBM patients with established tumors, is 
usually 3 months from detection (21).  
 Though promising, the recently-emerging strategy of cancer immunotherapy in the 
context of GBM tumors suffers from drawbacks and adverse side-effects in patients (16, 22-25). 
Thus, it is imperative to investigate for alternative tumor-specific therapies, which should serve 
as potential tumoricidal and onco-immunotherapeutic agents, while being innocuous to normal 
tissues. 
1.2 Curcumin and its potentiated forms as effective tumoricidal agents. 
Curcumin (CC) ((1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) 
(chemical formula: C21H20O6) is a polyphenolic component derived from the rhizome of the 
spice turmeric (Curcuma longa). Like many other naturally-derived polyphenols it has been 
shown to be an effective anticancer agent against a broad array of tumors including GBM, both 
in vitro and in vivo without being toxic to normal tissues (17, 18, 26-38). The use of CC as a 
potent anti-cancer agent was very promising in preclinical studies, but it's effectiveness in 
clinical trials has been limited. This is because CC's in vivo anti-tumor potency is severely 
restricted by its low systemic bioavailability due to its low plasma concentrations, insufficient 
tissue delivery, fast metabolic breakdown, and short half-life (39, 40).  
 Over the past few years, our research group has demonstrated that the anti-tumor activity 
of CC can be drastically improved by enhancing its bioavailability via stabilization, targeting and 
chemical modifications using diverse novel methods (27-29, 33, 34, 41, 42). One such strategy, 
as reported in our previous studies, shows that this drawback of low solubility and systemic 
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stability can be tackled by chemically linking CC to an antibody (CC-Ab) for superior tumor 
tissue retention, stability and solubility in vivo (28). The current study utilizes a comparable 
strategy in which we created a curcumin-CD68 antibody adduct (CC-CD68Ab) by linking CC to 
the CD68 antibody via a cleavable ester bond.  It should be noted that the glycoprotein CD68 is 
highly expressed on human, murine and patient-derived GBM cells in vitro and in vivo (29, 41, 
42). Thus, using this rationale, we targeted CC-CD68Ab to the mouse and human GBM cells and 
on an orthotopic GL261-implanted GBM mouse model to achieve tumor elimination (22, 29, 
42). Although this strategy augmented the potency of CC several fold and was successful in 
rescuing 10% of the GL261-implanted GBM mice by delivering the CC-CD68Ab adduct intra-
cranially (invasive), a less invasive mode of delivery was required to translate this mode of 
therapy to potential clinical settings (29). Delivering the CC-CD68Ab adduct into the GBM brain 
remained a difficult task due to the difficulties faced by large molecules, such as antibodies in 
crossing the blood brain barrier (BBB) (43). Here, we show for the first time that intranasal (IN) 
infusion of the CC-CD68Ab adduct surmounts this obstacle, thereby completely rescuing 50% of 
GL261-implanted GBM mice.  
 Our second strategy was to utilize a commercially available, stable, highly-bioavailable 
form of CC called Curcumin Phytosome-Meriva® (CCP), in which each CC molecule is 
associated via molecular interactions with the phospholipid phosphotidylcholine (PC) (for details 
please see method section 2.8) (40, 44-46). CCP was also highly potent when delivered 





1.3  Curcumin: A potential oncoimmunotherapeutic agent in GBM therapy. 
Earlier studies demonstrate the role of many plant-derived dietary polyphenols in stimulating the 
immune system (19, 47, 48). It is also known that various genetic aberrations can trigger 
carcinogenesis and cancer could be prevented if such abnormally generated cells are eliminated 
by a vigilant immune system (49). Thus it is likely that plant-derived dietary components like CC 
may play a significant role in potentiating our immune system to eliminate tumors.  Previous 
studies have supported this notion and have exhibited the unique role of CC in onco-
immunotherapy in stimulating a battery of tumoricidal peripheral immune cells like T-cells, 
dendritic cells and macrophages in eliminating tumors (17-19, 26, 50-52). Even though the 
normal brain is not expected to possess the wide array of  lymphocytes present in the peripheral 
system, it has been shown that under injury, infection and tumor condition, there is recruitment 
and activation of a wide array of inflammatory immune cells (23, 53-56).  
1.4  Involvement of the Brain’s Innate Immune System in Curcumin-Mediated Elimination 
of GBM: Investigating the Role of Tumor-Associated Microglia/Macrophage. 
Reports indicate that the concentrations of CCP-associated CC are far below the IC50 of CC for 
the GL261 cells (40, 44-46). Moreover, it is expected that intra-brain concentrations of CC from 
CC-CD68Ab and CCP would be even lower than the plasma concentrations of  CC (35, 45). Yet, 
CCP and CC-CD68Ab treatment caused GBM elimination and rescue of 50-60% of the GL261-
implanted GBM mice. As a cue to this striking observation, we also observed a CC-evoked 
dramatic repolarization of tumor-associated microglia/macrophages (TAM) from the tumor-
promoting and immunosuppressive M2-like state to the tumoricidal M1 state  in the GBM-
bearing CC-treated and rescued mice (42, 57-60). These results were fascinating because innate 
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immune cells like microglia and macrophages are the first line of defense against pathogenic 
infections and tumors (61). Moreover, among the battery of immune cells, brain chiefly harbor 
microglia, which in their pro-inflammatory M1 phenotype can eliminate tumors directly as well 
as indirectly by functioning as specialized antigen-presenting cells and by causing activation and 
recruitment of other tumoricidal innate immune cells like Natural Killer (NK) cells and 
peripheral M1-type macrophages (42, 50, 53, 55, 59, 60, 62, 63). It has also been demonstrated 
that in GBM, a major fraction of the tumor mass is constituted of  M2-type TAM (around 40%), 
thus skewing their activation phenotype to the tumoricidal M1 state by therapeutic intervention 
holds immense potential in the context of GBM immunotherapy (42, 58, 64, 65). 
 Our studies here show that CC (as CC-CD68Ab and CCP), even at such relatively low 
concentrations, not only cause a permanent repolarization of the TAM in GBM from the pro-
tumor M2-like phenotype to the anti-tumor M1-like state, but also triggers intra-tumor 
recruitment of NK cells from the peripheral system (24, 42, 66). We also demonstrate 
quantitatively for the first time that a part of this CCP-induced, intra-GBM M1-polarized TAM, 
are activated M1-like recruited macrophages (50-60% of TAM). IL12 release from these 
activated M1-like macrophages is expected to play a crucial role in this intra-tumor recruitment 
of activated NK cells from the periphery (42, 66-68).   
1.5  Role of Intra-tumor NK cell recruitment in Enhancing the M1-phenotype of the TAMs 
Upon CCP Treatment. 
Studies have revealed that M2 macrophages inhibit the activation and cytotoxic functions of NK 
cells. Upon activation NK cells are known to stabilize M1-type TAM, while silencing M2-type 
TAM (69-72). By treating  GBM mice with or without i) the elimination of peripheral NK cells 
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ii) IL12-mediated NK cell signaling, we show that the CCP-induced activated NK cells play a 
major role in GBM elimination by repolarizing the TAM from M2 to the M1 state and 
eliminating the GBM cells as well as the GBM stem cells (73). Recruitment of both  these 
tumoricidal peripheral immune cell types (M1-like macrophages and activated NK cells) are 
possibly governed by the M1-linked chemokine macrophage chemotactic protein (MCP-1) (aka 
CCL2). Our data suggested that MCP-1 released the by CCP-evoked M1-like microglia activate 
and recruit M1 macrophages to cause tumor elimination (56, 74-81). It has also been shown that 
MCP-1 released from M1 TAM can cause NK cell activation and recruitment into the brain (67, 
68, 81-86).  
 Our studies reveal that these activated NK cells play a major function in amplifying the 
M1 phenotype of TAM and directly killing tumor cells (66, 73). To the best of our knowledge, 
we demonstrate for the first time, via a quantitative approach that NK cells play a key role in 
GBM elimination by enhancing the magnitude of the CCP-mediated TAM repolarization from 
M2 to M1 state to cause greater elimination the GBM cells and GBM stem cells which could 
possibly be responsible for bringing about the immunotherapeutic remission of the GBM-
harboring mice. Elimination of the GBM stem cells are essential as past studies have shown that 
these seldom proliferating and chemotherapy-resistant GBM stem cells augment resistance to 
radiotherapy and get induced to proliferate after contact with ionizing radiation (13, 87, 88).  As 
a result, even after the tumor is surgically removed there are incidences of GBM recurrence, 
which subdues the already immunocompromised patient (11, 14).  
 Cognizant of the high mortality of GBM patients who surrender to palliative care, we 
have turned our attention to GBM immunotherapy. Our research reveals a pioneering, and 
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straightforward strategy to turn  the body's own immune system against GBM (89-92). Thus, our 
studies establish that CCP can indirectly eliminate GBM tumors by activating the cells of the 
innate immune system (17-19, 40, 42, 51, 52). This study also provides new insights on the 
relationship between the brain tumor microenvironment and the peripheral innate immune 
system. Inspired by the promises of cancer immunotherapy (89-92), our research elucidates an 
innovative, safe and simple approach of onco-immunotherapy in GBM. 
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Chapter 2: Methods and Materials 
2.1 Cell culture of human, murine and patient-derived GBM cells: The human GBM cells, 
U87MG was cultured in RPMI 1640  supplemented with 10% (v/v) FBS (Fetal Bovine Serum) 
and 1% (v/v) Penicillin-Streptomycin (Pen-Strep) with 5 mM glutamax.  For the purpose of drug 
treatment and dose-response effect, the cells were treated in Neurobasal medium supplemented 
with 2% (v/v) B-27 supplement and 1% (v/v) (Penicillin-Streptomycin) Pen-Strep (29).  
 GL261 mouse glioblastoma cells were cultured in RPMI 1640 supplemented with 10% 
(v/v) FBS and 50 µg/ml Gentamicin. For the purpose of drug treatment and dose-response effect, 
the cells were cultured in RPMI medium containing 1% (v/v) ITS (insulin-transferrin-selenium- 
Gibco BRL) and 50 µg/ml Gentamicin (42, 58).   
 For culturing the human patient-derived GBM994, GBM46 and GBM6 (weakly-
adherent) cell lines, T75 flasks were adequately coated with poly-lysine (0.1mg/ml in H2O) for 
30 minutes at room temperature (RT), followed by rinsing the flask with sterile H2O. 
Subsequently, Laminin (Sigma L2020) (75 µL of stock/10 ml sterile PBS) was used to coat the 
flask followed by incubation for 2 h at 37 °C. The cells were seeded, cultured and assayed in 
StemPro media (Invitrogen–Life Technologies A10509-01) (42). 
2.2 Generation of glioblastoma patient-derived lines GBM6, GBM46, GBM994 from three 
different glioblastoma patients.  The human patient-derived glioblastoma cell lines, GBM6 and 
GBM46 were created at the Mayo Clinic, Rochester, Minnesota according to these reports (93, 
94).  These GBM samples were obtained and processed with approval of the patients and 
endorsement of the Institutional Review Board of the Mayo Clinic.  
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 The other human patient-derived glioblastoma cell line GBM994 was created in a similar 
manner by Boockvar and coworkers (unpublished data). The sample for GBM994 was obtained 
from a patient with a left temporal lobe GBM recurrence after radiation and temozolomide 
treatment. It was obtained with the permission of the patient and approval of the Weill Cornell 
Institutional Review Board (42). 
2.3 Animals:  Adult C57BL/6 male mice (2–6 months old) were utilized for all the studies. The 
mice were bred in the College of Staten Island (CSI) Animal Care Facility and kept on a 12-hr 
light/dark cycle with ad libitum access to food and water. All the mice were handled and utilized 
for all the studies (including survival surgery, tumor implantation, drug treatments, euthanasia 
etc) governed by an animal protocol approved by the Institutional Animal Care Committee 
(IACUC) of the CSI (CUNY) (approval # 11−008). 
2.4 Immunocytochemistry:  Poly-lysine-coated wells (0.1mg/ml in H2O) were utilized for 
plating of the cells. The cells in the wells (with or without drug treatment, as applicable) were 
rinsed with PBS, fixed in 4% paraformaldehyde (PFA), rinsed three times with PBS, treated with 
blocking solution (10% goat serum in PBS plus 0.1% Triton X-100). The cells were then 
immunostained using primary antibody (Ab) anti-CD68 (H-255) (sc9139) (1:200), followed by a 
secondary antibody (Alexa Fluor 488 goat anti-rabbit) (1:1,000). The cells were subsequently 
treated with HOECHST33342 (10 µg/ml) for 20 min at room temperature. CD68 Ab-stained 
images were acquired using the excitation wavelength of 488 nm. The HOECHST33342 images 
were captured using the excitation wavelength of 405 nm. Confocal imaging was conducted 
using a Leica SP2 microscope from multiple fields which were randomly chosen (42, 58). The 
experiment was repeated three times. 
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2.5 Research design: Our earlier reports have standardized a condition to generate an orthotopic 
GBM tumor in 100% of the GL261-implanted C57BL6 mice (a syngeneic mouse model) (29, 42, 
58). Using this method, GBM-bearing mice were generated and then randomly divided into 
multiple cohorts for Vehicle and drug treatments (as discussed below). Although our prior 
studies had demonstrated the generation of GBM tumor by sacrificing parallel groups of GL261-
implanted mice, in the experiments included here, the researcher was completely blinded from 
the actual status of a GBM tumor in any GL261-implanted mouse placed in any of these groups 
during drug treatment. However, after extrication of the GBM-harboring brains (as described 
below) from all the groups, all the brains were subjected to near-IR scanning to ensure the 
presence of established tumors (as detailed below) (29, 42, 58). n ≥ 3 for each group (Please see 
Fig. 8, 18 and 20 for details). 
2.6 Implantation of cancer cells in mice:  On day 1, mice were anesthetized by intra-peritoneal 
(IP) infusion of 100-mg/Kg ketamine and 10-mg/Kg xylazine. For the long-term survival study 
pilot experiment, 80,000 GL261 cells were suspended in 5 µl of sterile PBS and were implanted 
into the right forebrain [coordinates: with respect to the Bregma (in mm) AP = 2.5; L = –1.1; D 
=1.5] of each anesthetized mouse under aseptic conditions, utilizing a stereotactic set up (KDS 
Model 310 plus infusion-withdrawal syringe pump) at 1 µl/min. For each of the larger 
experiments in long-term survival and short-term studies, 10
5
 GL261 cells in 5 µl of sterile PBS 
were implanted into the right forebrain, as elaborated above on day 1. The wound area was then 
treated with an antiseptic solution and closed with suture clips, and the mice were placed under a 
warming lamp to recover. On day 10, the GBM tumors usually become established and reaches 
5-10% of the brain volume (brain volume being about 500-600 µl for an adult C57BL6 mouse), 
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so the earliest time-point for starting any treatment (as detailed below) was day 11 (28, 29, 58). n 
≥ 3 for each group (Please see Fig. 8, 18 and 20 for details). 
2.7 Preparation of Dylight 800-CD68Ab and curcumin-CD68Ab adducts: To synthesize the 
Dylight800-CD68Ab adduct, firstly, 100 µl (20 µg) of CD68 antibody (sc9139) in 0.01 M PBS 
was mixed with 0.05 M borate buffer (pH 8.3, 8 µl). The mixture was vortexed, and added to a 
lyophilized tube of Dylight 800-NHS ester (Thermo Fisher Scientific). The mixture was 
subjected to gentle vortexing, followed by incubation at room temperature for 1 hour in the 
absence of light.  Next, 100 µl slurry of a dye-removal resin (Illustra Microspin G-50 columns 
GE Healthcare, Product No. 27-5330-01) was added to the reaction mixture.  The slurry was 
vortexed and moved to a spin column and centrifuged at 2000 rpm to gather the eluate in a 
microcentrifuge tube placed at the bottom. This eluate was aliquoted, frozen, lyophilized, and 
stored at -20 °C under nitrogen, away from light (29, 42, 58).   
 To prepare the CC-CD68Ab adduct, a 10-fold molar excess of succinimidyl curcumin 
carboxylate (CC-NHS ester) was dissolved in DMSO (10% v/v) and was added to CD68 
antibody (20 µg) (sc9139) in 50 mM sodium bicarbonate buffer (pH 8.5). the mixture was stirred 
vigorously in capped, brown vials held in ice in the absence of light for three hours.  After this 
coupling reaction between the CC-NHS ester and the CD68Ab, the adduct was purified via a 
spin purification column, and eluted as described earlier for the purification of Dylight800-CD68 
antibody adduct (28, 29).  The eluate was divided into aliquots, each containing 120 pmole of 
antibody-linked CC, lyophilized, and then stored under nitrogen at -80 ° C, away from light. The 
curcumin:Ab ratio in the CC-CD68Ab adduct (1:1) was determined by MALDI-TOF (29, 42, 
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58). This known mass of CD68Ab bound CC was used to calculate the drug concentrations used 
in all the in vitro and in vivo studies. 
2.8 Curcumin Phytosome Meriva (CCP): Curcumin Phytosome Meriva (CCP) is a patented 
formulation with higher bioavailability of curcuminoids (CC) than free CC, prepared by allowing 
a definite mass of CC to bind (in an organic solvent) to an equimolar mass of 
phosphatidylcholine (PC) through interactions such as hydrogen bonding between the hydroxy 
groups of CC and the polar head group of PC. Upon removal of the organic solvent and 
dispersion in an aqueous medium the hydrophobic side chains of PC would be expected to 
envelop the hydrophobic motifs of CC to keep it protected and improve the stability and 
bioavailability of CC in vivo (44, 45, 95). Each commercially available CCP capsule (each 500 
mg solid capsule) contained 96 mg of PC-bound CC along with excipients. This defined mass of 
PC-bound CC was used to calculate the drug concentrations used in all the in vitro and in vivo 
studies (42).  
2.9 Drug treatments and determination of IC50: Aliquots of CC-CD68Ab and CCP (having a 
known mass) were suspended in the required volume of medium (serum-free RPMI with 1% ITS 
supplement for GL261 and stem-pro medium for GBM994, GBM46, and GBM6 cells), serially 
diluted (in the respective medium) to obtain a series of working concentrations of the two drugs, 
which were tested on GL261, GBM994, GBM46 and GBM6 cells to determine their anti-tumor 
potencies in vitro. The cells were treated with drugs when the wells reached 30% confluence. 
Cells were visually monitored for membrane blebbing and degradation 48 hours after treatment 
by light microscopy.  After 96 hours of treatment, the medium in each well was aspirated, and 
the cells were gently rinsed three times with PBS. Next, the cells were incubated at 37 °C for 45 
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min with 10% WST-1 (v/v) (Clontech, Mountain View, CA) diluted in serum-free DMEM (v/v) 
(29, 42, 58), and the absorbance of the resultant solution monitored at 440 nm using a plate 
reader (Molecular Devices). Dose dependent response curves were calculated from the 
absorbance to determine the IC50 of the drugs for all the brain tumor cell lines mentioned above.  
Microsoft Excel® was used for graphical analysis. The experiment was repeated three times. 
2.10 Intranasal delivery of the Dylight800-CD68Ab and the CC-CD68Ab adduct: To 
determine the most efficient non-invasive strategy for CC-CD68Ab delivery into GBM brains, 
the GBM mouse was anesthetized, placed in the supine position, and CD68Ab-Dylight800 
containing 60 µg (400 pmole) of  antibody in 30 µl of PBS was applied in 3-µl drops alternately, 
every two-three minutes, to each nostril and was allowed to be snorted in intranasally (IN). The 
mouse was allowed to recover and then sacrificed after six hours. The brain was extricated 
without fixing and the soft, gel-like tumor-containing brain, was placed with its dorsal face up on 
the near-IR scanner, scanned from the ventral side and the data was analyzed as mentioned in a 
later section (please see 'Post-mortem brain examination by ex vivo near-IR scanning and post-
mortem determination of GBM Tumor load').  Subsequently, the brain was in fixed in PFA, 
placed with ventral face up and imaged using a bright-field camera from the ventral side. 
  On the tenth day after implantation, the GBM mice were anesthetized, placed in the 
supine position, and 120 pmoles of CC-CD68Ab adduct (CC:Ab: 1:1) (containing 18 µg of 
CD68 Ab) dissolved in 30 μl of sterile PBS was applied as 3-μl drops using a micropipette, 
alternately, every two-three minutes, to each nostril and allowed to be snorted in. In a similar 
fashion, IN application of Vehicle (30 µl sterile PBS) was conducted every 72 hours, as 
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described above for IN application of CC-CD68Ab. n ≥ 3 for each group (Please see Fig. 8 for 
details). 
2.11 Intra-peritoneal delivery of CCP on GL261 implanted mice: Curcumin Phytosome 
Meriva (CCP) (96) sold as a supplement for joint health, as mentioned before, contains 96 mg of 
PC-bound CC in 500 mg of an amorphous solid in each capsule.  For i.p. administration of CCP, 
10 days post-implantation of 10
5
 GL261 cells, each 30-g mouse received i.p. injections of 
Vehicle (PBS) or a CCP emulsion containing 2 mg of CCP in 200 µl of PBS every 72 hours. 
CCP was dispersed by vortexing it vigorously in 200 µl of sterile PBS. The resultant insoluble 
solids were allowed to settle for 2 min, and then the translucent supernatant (PC-bound CC) was 
used for i.p. injection into each mouse (42, 73). 
 For the long-term experiments resulting in rescue of GBM mice, (i.p. administration of 
CCP was performed every 72 hours for one month (42, 73). n ≥ 3 for each group (Please see Fig. 
8 for details). 
 For the short-term experiments, daily i.p. administration of CCP was initiated from day 
12 and continued until day 16. Each 30-g mouse received i.p. injections of sterile PBS (Vehicle 
group) or a CCP emulsion (for the “CCP”, “CCP+NK1.1”, and “CCP+IL12Ab” groups), in the 
same amounts as used in the long-term experiments (73). n ≥ 3 for each group (Please see Fig. 
18 and 20 for details). 
2.12 Post-mortem brain examination by ex vivo near-IR scanning and post-mortem 
determination of GBM Tumor load: Near-IR images were acquired using the Odyssey® 
Imaging System (LI-COR Biosciences, Nebraska). Brightfield images were acquired using a 
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digital camera.  The Dylight800 fluorescence (~800 nm) from the tumor targeted Dylight800-
CD68Ab was pseudocolored green  (tumor load) and the enhanced autofluorescence of the 
normal brain tissue (~ 700 nm, autofluorescence) was pseudocolored red (29, 42, 58, 73). 
 To monitor tumor load, each mouse was anesthetized, intranasally treated with the 
Dylight800- CD68Ab adduct on day 16 (post-implantation) as described earlier (29, 42, 58), and 
then scanned after 24 h (following anesthesia) using the Odyssey near-IR scanner. The (tumor 
load and the enhanced autofluorescence of the brain tissue were determined via  ImageJ, in all 
experimental groups to ensure the presence of established GBM tumors. The tumor tissues along 
with the peripheral areas were extricated and processed for further analyses (29, 42, 58, 73). n ≥ 
3 for each group (Please see Fig. 8 and 18 for details). 
2.13 Immunohistochemistry of brain tumors and scar tissue region: Coronal sections of 30 
µm thickness were prepared from 4% paraformaldehyde-fixed and 30% sucrose-pre-soaked 
GBM tumors-bearing mouse brains (for both the long-term survival studies and short-term 
studies) or scar tissue (the rescued brains from the long-term survival studies) (29, 42, 58). 
Randomly chosen sections containing tumor tissue and scar tissue area were processed as 
follows for antigen retrieval (except for Iba1/IL-12/IL-10 staining): incubation with 
formamide:2xSSC (1:1), 55 °C for 2 h, and then 5 min in 2xSSC (30 mM sodium citrate, 30 mM 
sodium chloride) at room temperature (RT). Antigen-retrieval for Iba1/IL-12/IL-10 staining was 
performed by incubating the sections with 0.1% (w/v) pepsin (Thermo Fisher Scientific, 
AC417071000) dissolved in 0.01 N HCl for 20 min at RT, followed by two PBS washes (72). 
All the sections were blocked overnight at 4 °C in blocking buffer (0.1 % Triton X-100, 3% goat 
serum and 10% rabbit serum in 100 mM PBS). Subsequently they were treated overnight with 
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the following primary antibodies: anti-Iba1 (goat IgG)(C20) (sc28530) (1:50), anti-iNOS (rabbit 
IgG) (NOS2 sc-651) (1:100), anti-arginase1 (rabbit IgG) (sc-20150) (1:100), anti-p65 (NF-kB) 
(mouse IgG) (sc-8008) anti-P-Ser
276
-p65 (NF-kB) (rabbit IgG) (sc-101749) (1:100), anti-STAT-1 
(rabbit IgG) (Sc-592) (1:100), anti-P-Tyr
701
-STAT1 (mouse IgG) (sc-8394) (1:100), STAT3 
(rabbit IgG) (sc-7179) (1:100), P-Tyr
705
-STAT3 (goat IgG) (sc-7993) (1:100), NKp46 (rabbit 
IgG) (sc-292796) (1:100), IL-12p40 (rabbit IgG) (sc-7926) (1:100), IL-10 (goat IgG) (sc-1783) 
(1:100), anti-CD133 (goat IgG) (sc-19365) (1:50), anti-Sox-2 (mouse IgG) (sc-365823) (1:50), 
anti-RM0029-11H3 (macrophage marker) (rat IgG) (sc101447) (1:50) and MCP-1 (Rabbit IgG) 
(Thermo Fisher Scientific #PA1-22488) (1:200). All the primary antibodies were diluted in 2% 
goat serum and 2% rabbit serum and 0.1% Triton X-100 in PBS (GRT-PBS). '2° only' control 
sections were incubated overnight at 4 °C in the blocking buffer but did not receive any of the 
above-mentioned primary antibody. After washing with PBS (three times), the respective 
secondary antibodies (Alexa Fluor 488 goat anti-rabbit, Alexa Fluor 633 goat anti-rabbit, Alexa 
Fluor 568 goat anti-rabbit, and Alexa Fluor 633 goat anti-mouse, Alexa Fluor 633 rabbit anti-
goat, Alexa Fluor 633 goat anti-mouse, Alexa Fluor 568 rabbit anti-goat, Alexa Fluor 568 goat 
anti-mouse) (Invitrogen), and goat anti-rat-phycoerythrin (sc3740)) (1:1,000 dilutions in GRT-
PBS) were added to all the sections treated with the primary antibodies as well as to the '2° Ab 
only' controls. Following overnight incubation at 4 °C and three washes with PBS, the sections 
were treated with HOECHST33342 (10 µg/ml) for 30 min at RT. The sections were washed 
three times with PBS and mounted on microscope slides with Gold anti-fade mounting fluid 
(Thermo Fisher Scientific, NC9143637). Confocal Imaging was conducted using a Leica SP2 
microscope from multiple randomly chosen fields encompassing regions in and around the tumor 
(for all the samples of the four groups from the short-term study and the 'Vehicle' samples of the 
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long-term rescue study) (42) and scar-tissue region (for the rescued samples of the long-term 
rescue study) (42, 58, 73).  
 ImageJ (NIH) was used to obtain the fluorescence intensities. The fluorescent intensity of 
all the above-mentioned antibodies were normalized to HOECHST33342 intensity (blue).  Since 
p65 NF-kB, STAT1 and STAT3 displayed both induction as well as phosphorylation-mediated 
alterations, the HOECHST-normalized staining intensities were expressed both as P-p65 NF-
kB/p65 NF-kB, P-STAT1/STAT1 and P-STAT3/STAT3 as well as P-p65 NF-kB/HOECHST, P-
STAT1/HOECHST and P-STAT3/HOECHST. Wherever essential, antibody stained cells 
(single, double or triple-stained) were counted using ImageJ and the data were expressed as 
percentage of total count with respect to the Vehicle group (73). n ≥ 3 for each experimental 
group and for each type of staining experiment (Please see Fig. 10, 11, 13-17, 19, 21-23 and 25-
30 for details). 
2.14 Flow cytometry of immunostained brain tumor and scar tissue cells:  The brains from 
the GL261 implanted, morbid mice (Vehicle-treated control mice), the rescued mice (GL261 
implanted, CCP and CC-CD68Ab-treated mice living more than 120 days) (i.e. from the long-
term studies) were extricated without fixing (after anesthesia), and rinsed twice with PBS. The 
brains of the GL261 implanted, GBM mice of the four groups (Vehicle, CCP, CCP+NK1.1 and 
CCP+IL12Ab) from the short-term studies were also processed in the same fashion on day 17 
(73). 
 Next, only the cells from the tumor area (for long-term 'Vehicle' groups  and all the short-
term groups) (the tumor core, periphery and most area around it) and scar tissue area (treated, 
rescued long-term groups) (scar tissue core, periphery and most area around it) from these 
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unfixed brain tissues were dissected out and gently dissociated by mild trypsinization using 
trypsin-EDTA (0.25%) and repeated trituration using a fire-polished Pasteur pipette to produce 
single cell suspensions (42, 58, 73, 97-99). The dissociated cells were filtered through a sieve of 
100 µm pore size to remove clumps and undissociated tissues and were subsequently fixed using 
freshly made 4% para-formaldehyde (PFA). The fixed cells were counted and stored in PFA at 4 
°C. Around 2 million fixed cells from each animal were used for immunostaining, using the 
method described under immunocytochemistry. Antibodies against Iba1 (C20) (1:50), iNOS 
(rabbit IgG) (NOS2 sc-651) (1:100), arginase1 (rabbit IgG) (sc-20150) (1:100), NKp46 (1:100), 
IL-12p40 (1:50), IL-10 (1:50), CD68 (H-255) (Rabbit IgG) (sc-9139) (1:50), Active-Caspase3 
(Asp175) (Rabbit IgG) (CST #9661) (1:100), and CD133 (1:50) were used for staining. Cells 
treated with the secondary antibody alone were used to demarcate the background. 
 Flow cytometry was performed using Accuri C6 flow cytometer (BD). For all the sample, 
events above 10
4
 forward and 10
3
 side scatter were gated, and 100,000 gated events were 
analyzed. Compensation was performed to minimize the spillover from each channel (FL1-A and 
FL2-A), subpopulations of cells appeared in different quadrants based on their respective 
fluorescence intensities. Events from autofluorescence and non-specific fluorescence from the 
“2° antibody only” samples appeared as a distinct population in the lower-left quadrant (LL 
quadrant). The double-stained fluorescent events from CD68(+)/Iba1(+), ARG1+/Iba1(+), 
iNOS+/Iba1(+), IL10+/Iba1(+), IL12+/Iba1(+), and CD68(+)/Active-Caspase-3(+) cells 
appeared as sub-populations in the upper right (UR) quadrant within the coordinates 520 nm 
(green for CD68, ARG1, iNOS, IL-10 and IL-12) (FL1-A) and 580 nm (red for Iba1 and Active-
Caspase-3) (FL2-A). Single-stained fluorescent events from the scatter plots and from Nkp46(+) 
and CD133(+) cells appeared as sub-populations in the upper left (UL) quadrant within the 
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coordinate 580 nm (red) and lower right (LR) quadrant within the coordinate 520 nm (green). 
For comparing between groups integrated fluorescence intensity was calculated by multiplying 
the number of positive events (single stained or double stained cells) by the mean fluorescence 
intensity (58, 72, 73). n ≥ 3 for all experimental groups and for each type of staining experiment 
(Please see Fig. 12, 18, 19, 20 24 and 27 for details). 
2.15 Hematoxylin and eosin (H&E) staining of brain sections: Vehicle-treated GBM and CC-
treated and rescued brain sections were soaked in Harris hematoxylin for 2 min followed by 
washing with water, acid-alcohol, water, and ammonium hydroxide solution.  Then the sections 
were washed with running water for 5 min, and once with 80% Ethanol. Next eosin staining was 
performed for 5 min, followed by rinsing with 95% ethanol, 100% ethanol, and xylene. Then the 
sections were mounted in Permount and microscopic study was performed using an upright 
Nikon microscope fitted with a Spot digital camera (29, 42). Three samples per group was used 
for staining. 
2.16 Neutralization of NK cells by intra-peritoneal infusion of NK1.1 Ab: On day 11 from 
implantation of 10
5
 GL261 cells, each mouse in the CCP+NK1.1 group received i.p. infusion of 
NK cell-neutralizing anti-NK1.1 antibody (Mouse IgG) (BD, 553162) (100 µg) (100). Mice of 
the other two groups (Vehicle and CCP) received intra-peritoneal injection of normal mouse IgG 
(Invitrogen, 31881) (100 µg). As a negative control for CCP and a proof of NK cell 
neutralization, GBM mice from a fourth group termed 'NK1.1' were also injected (i.p.) with the 
NK cell-neutralizing anti-NK1.1 antibody (PK136) (100 µg) on day 11, followed by i.p. 
treatment of Vehicle (PBS). After five injections of Vehicle or CCP, each mouse was sacrificed, 
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the brain tumor divided into two parts for immunohistochemistry (IHC) and flow cytometry 
analysis as detailed above (73). n ≥ 3 for each experiment (Please see Fig. 18 for details). 
2.17 Neutralization of IL12-mediated signaling in NK cells by intra-peritoneal infusion of 
IL12 Ab: On day 11 and day 14 from implantation of 10
5
 GL261 cells, each mouse in the 
CCP+IL12Ab group received intra-peritoneal infusion of IL12-neutralizing rat Anti-IL12 
(p40/p70) antibody (BD, 554475) (100 µg, each dose) (69, 72, 73). Mice of the other two groups 
(Vehicle and CCP) received Rat IgG (100 µg/ mouse, Thermo Fisher Scientific, 31888) and 
subsequent reagents (Vehicle or CCP) as mentioned in the last section. After five injections of 
Vehicle or CCP, each mouse was sacrificed and the brain tumors were divided into two parts for 
IHC and flow cytometry analysis as detailed earlier (73). n ≥ 3 was used for each experiment 
(Please see Fig. 20 for details). 
2.18 Statistical analysis: Two-tailed t-tests with unequal variance were employed when 
comparing between two groups while one-way ANOVA were utilized when comparing three 
groups. p ≤ 0.05 was considered as significant. 
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Chapter 3: Results 
3.1 Mouse glioblastoma (GL261) cells, human glioblastoma (U87MG) cells, and patient-
derived GBM explants (GBM6, GBM46 and GBM994) express high levels of CD68: 
Although curcumin (CC) has a strong cytotoxic activity toward a diverse range of cancer cells 
(33, 35, 101, 102), our previous studies have shown that melanoma cell-implanted established 
brain tumors treated by CC alone failed to eliminate these tumors (35). Subsequently, we 
reported that covalent linking of CC to a melanoma cell-specific antibody dramatically increased 
its anti-cancer potency (28). Using the same approach, we investigated for presence of an antigen 
that would have significantly higher expression on the surface of glioblastoma cells than the 
other brain cells, which can then be used to target these GBM cells using the antibody-CC adduct 
approach (28). CD68 is a 110-kDa transmembrane glycoprotein, that is known to be expressed 
by cells from the monocyte lineage (macrophage/microglia) (103).  Additionally, it is known that 
in malignant astrocytoma cells, which constitute GBM tumors, CD68 expression is very high 
(104). So, in the search for the most suitable surface antigen to target GBM we investigated the 
presence of CD68 in a few GBM cell lines.  
 As expected, immunocytochemical staining analysis revealed the expression of high 
levels of CD68 on the surface of GL261 as well as the human glioblastoma cells U87MG in 
culture (Fig. 1) (29). 
 In order to translate our finding to potential clinical settings, we also investigated the 
expression and intra-cellular localization of the CD68 antigen in three patient-derived GBM cell 
explants (GBM6, GBM46 and GBM994). As shown in Fig. 2, all the three cell types express 
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CD68, with GBM6 cells expressing lower levels of cell-surface CD68 and higher levels of 
nuclear CD68 (42).   
 
Figure 1. CD68 is highly expressed by both mouse (GL261) and human (U87MG) GBM cells in 
culture. (a) (i) and (b) (i) CD68 expressing cells (green) were counterstained with the nuclear dye 
HOECHST33342 (HCHST) (blue). (a) (ii) and (b) (ii) Cells in '2° Ab only' controls (showing the 
absence of green staining) were marked by HCHST staining. Scale bar: 47.62 µm (20x) (29). 
 
 












Fig. 2. Patient-derived GBM explants express CD68: (A) Surface CD68 staining in patient-derived 
GBM46 cells. (B) Lower surface expression and higher nuclear CD68 staining in GBM6 cells. (C) Higher 
surface expression of CD68 in GBM994 cells. Scale bar: 47.62 µm (63x) (42). 
 
3.2 Vehicle-treated, GL261-evoked established GBM tumor cells showed high CD68 
expression, whereas the TAM were chiefly CD68
low
, Iba1(+) and RM0029-11H3(-) 
microglia:  In order to verify the suitability of CD68 for targeting GBM cells in vivo, coronal 
sections of GL261 tumor-bearing Vehicle-treated brains were analyzed by immuno-staining with 
the following antibodies: CD68 (Fig. 3A and B), Iba1 (marker for activated 
microglia/macrophage) (Fig. 3C and D) and RM0029-11H3 (specific marker for activated 
macrophage) (Fig. 3E) (42, 58, 73, 105).  Data shown in Fig. 3 demonstrate high levels of CD68 
expression (green) on the tumor cells, which were present chiefly at the tumor core. Staining, 
using the activated microglia/macrophage-selective Iba1 antibody (red) showed the existence of 
a large number of CD68
low
 microglial cells, mainly located in the tumor periphery (Fig. 3D, E, 
F, left panel, green), but were not stained with the activated macrophage-specific (RM0029-
11H3) antibody (red) (Fig. 3C).  Interestingly, survival studies from glioma patients have shown 
that CD68 tumor staining has prognostic importance, as higher antigen expression is associated 
with shorter survival (106). Therefore, higher expression of CD68 in the GBM cells was an ideal 




Fig. 3. Vehicle-treated, GL261-evoked established GBM tumor cells showed strong CD68 expression, 
whereas the TAM were chiefly CD68
low
 and Iba1(+) (marks both activated microglia and 
macrophages) but RM0029-11H3(-) (macrophage specific marker) microglia (A and B) CD68high 
(green) staining of tumor cells. (D and E)  Large number of cells in the tumor periphery stained for Iba1 
(marks both activated microglia and macrophages).  (F)  These peripheral TAM were CD68
low
 (green) and 
strongly stained for Iba1 (red). HOECHST33342 (blue) stained the nuceli. (c) These TAM did not stain for 
RM0029-11H3 (macrophage specific marker) (far red). (G, H, I) No non-specific staining was observed 
with any of the 2° antibodies.  Scale bars:  (20X) 129.64 µm; (63X) 41.16 µm (29). 
 
3.3 Attachment of CC to CD68 antibody causes a dramatic enhancement of CC's cytotoxic 
potency on GBM cells in vitro: In light of our previous data, we performed the synthesis of CC-
CD68Ab adduct by covalently linking CC through a cleavable linkage to the CD68 Ab and 
subsequently purified and isolated the adduct (Fig. 4A) (28). Our MALDI-TOF analysis showed 
that one molecule of CC was linked to one CD68 Ab molecule in the adduct (Fig. 4B and C), 
which enabled us to calculate the concentration of CD68Ab-linked CC for all subsequent in vitro 
and in vivo studies. We have shown that the targeting antibody without the attached CC molecules 
does not kill GL261 cells (28) whereas the CC-CD68Ab was readily taken up by the GL261 cells  
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in vitro (within 2 hours) causing intra-cellular CC release (marked by an increase in green 
fluorescence due to CC) and destruction of the targeted cell (29). This indicated efficient antibody-
mediated targeting of the CC molecules to the GBM cells, which should cause a significant 
increase in the cytotoxicity of targeted CC.  To prove this point, the GL261 cells were treated with 
various concentrations of CC and CC-CD68Ab adduct and post-treatment cell viabilities measured 
using WST-1 assays.  While free CC treatment yielded an IC50 of 15 µM (Fig. 5 A), treatment 
with the CC-CD68Ab yielded an IC50 of 125 nM ((Fig. 5 C). Thus, as hypothesized, targeted CC 
was 120-fold more potent in killing GL261 cells in vitro. Next, we wanted to investigate the 
effectiveness of the CC-CD68Ab adduct in killing the three patient-derived GBM cell explants 
(GBM6, GBM46 and GBM994) (Fig. 2).  Additionally, we wanted to determine if the previously 
observed levels of cell-surface CD68 (Fig. 2) did in any way influence the IC50 for CC-CD68 Ab 
(Fig. 6). Among the three patient-derived GBM cells, GBM994 displayed the highest sensitivity to 
CC-CD68 Ab (IC50, 25 nM)  (Fig. 6C). In comparison, free CC eliminated the GBM994 cells 
with an IC50 of 22.5 µM. Thus the targeted-CC (CC-CD68 Ab) was 900-fold more potent (Fig. 
6D). As mentioned before, the GBM6 cells expressing lower levels of cell-surface CD68 and 
higher nuclear CD68, displayed a higher IC50 for CC-CD68 Ab (still in the nanomolar range- 300 
nM, indicating much higher potency than free CC), suggesting that less cell-surface antigen 




(A) Scheme for synthesis of CC-CD68Ab Adduct 
 







Fig. 4. Synthesis and subsequent MALDI-TOF analysis of the CC-CD68Ab adduct (A) Synthetic 
steps to link curcumin (CC) to a glioblastoma-targeting antibody (CD68) through a cleavable arm. (B-C) 
MALDI-TOF analysis shows the presence of one CC molecule linked to one CD68 IgG molecule in the 
CC-CD68Ab adduct (29, 42).  
 
 
Fig. 5. CD68 Ab-linked CC (CC-CD68Ab adduct) is 120-times more potent than free CC in 
eliminating GL261 cells in culture. (A) Cytotoxic dose-response of free curcumin on GL261 cells (IC50 
= 15 µM). GL261 cells were treated with free CC (Neurobasal medium/<0.2% DMSO) or Vehicle 
(Neurobasal/DMSO) . (B) Dose response of CC-CD68Ab in GL261 cells (IC50 = 125 nM). GL261 cells 
here were subjected to treatment with CC-CD68Ab adduct or CD68Ab (negative control) (29, 42).   
 
3.4 Curcumin Phytosome (CCP)  eliminates GBM cells in culture with similar potency as 
free curcumin: Based on the CC content of CCP (see section 2.8), this PC-complexed 
preparation of CC was able to eliminate GBM994 and GL261 cells with  IC50 values (Fig. 7A, 
B) similar to the IC50 values observed for free CC (Fig. 5, 6). Though we observed similar 









Fig.6. Dose-response of targeted CC of the CC-CD68Ab adduct in patient-derived GBM explants. 
(A) GBM46 cells displayed a low IC50 for CC-CD68Ab (76 nM). (B) GBM6 cells had a relatively higher 
IC50 for CC-CD68Ab (300 nM, still in the nanomolar range). (C)  GBM994 cells had a very low IC50 













Fig.7. Curcumin Phytosome Meriva (CCP)  eliminates GBM cells in culture with similar potency as 
free CC (42). 
 
3.5 Both intranasal delivery of CC-CD68Ab adduct and peripheral CCP treatment were 
effective in causing elimination GL261-evoked GBM tumor and rescue of mice.   
We have previously shown that intra-cranial (invasive) treatment of GL261-implanted GBM 
mice with the CC-CD68Ab adduct successfully rescued 10% of the GBM mice (29). In order to 
translate this mode of therapy to potential clinical settings it was imperative to employ a non-
invasive method of delivery of the adduct (29). Delivering the CC-CD68Ab adduct into the 
GBM brain remained a challenge because of the difficulties faced by large molecules, such as 
antibodies in crossing the blood brain barrier (BBB) (43). Thus we wanted to verify if intra-nasal 
(IN) delivery of the adduct was a more practical and effective approach for GBM therapy (107).  
 In a pilot experiment, a Gl261-implanted GBM mouse was allowed to advance to 
morbidity (Fig. 8A) and then anesthetized for IN delivery of the CD68 Ab linked to a near-
infrared (Near-IR) dye Dylight800 (CD68-Dylight800 adduct) as illustrated in Fig. 8B. The 
CD68-Dylight800 adduct reached the brain and accumulated in the GBM, the location of which 
was detected and verified by both near-IR scanning and bright-field imaging (Fig. 8C and D).  
This confirmed that the CD68Ab could be delivered to the brain via the IN route.   
 In our earlier studies, free CC, delivered through the tail vein was able to reach the brain 
within fifteen minutes (35), but the transient level of CC achieved in the brain through this route 
was not sufficient to bring about a rescue of the tumor cell-implanted mice (28).  To test if the 
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PC-complexed preparation, CCP, was capable of producing an anti-tumor effect on GBM, we 
suspended 2 mg of the solid obtained from CCP capsules in 200 µl sterile PBS and injected the 
resultant translucent emulsion (i.p.) in each mouse from day 10 after implantation of 100,000 
GL261 cells. In parallel, GL261-implanted mice were also injected (i.p.) with sterile PBS 
(Vehicle-treated). Such i.p injection of CCP every 72 hours for one month was able to rescue 
60% of the GL261-implanted mice (observed up to 148 days from implantation) (Fig. 8E). In 
parallel, CC-CD68Ab adduct was administered IN every 72 hours from day 10 after Gl261 
implantation. Adduct treatment (120 pmole per mouse, per treatment) every 72 hours four times 
and then once every seven days (four times) caused remission of GBM in 50% of the GL261-
implanted mice (observed up to 148 days from implantation) (Fig. 8E). Around day 30, 50% of 
the Vehicle-treated mice were already dead whereas 100% of the IN-CC-CD68Ab-treated and 
90% of the CCP-treated mice were still alive (Fig. 8E). By day 90, all of the Vehicle-treated 
mice had succumbed to GBM, whereas 70% of the IN-CC-CD68Ab-treated and 60% of the 
CCP-treated mice were alive. Thus, our results demonstrate that suitably delivered CC not only 
rescues 50-60% of the GBM mice, but also prolongs the survival of the treated GBM mice. So, 
both these approaches for CC delivery seemed to be highly effective for GBM therapy.  
 We identified the tumor areas from the Vehicle-treated mice and scar tissue regions from 
the CC-treated and rescued mice by H&E staining in parallel brain sections (Fig. 9) and then 
used these areas and surrounding tissues from adjacent sections for our subsequent analyses. 
Being aware of CC's tumoricidal ability from our previous studies (28, 29), we looked for the 
presence of CD68
high
  GBM tumor cells at the tumor core of the Vehicle-treated mice (Fig. 9 A) 
and the scar tissue area of the CC-treated and rescued mice (Fig. 9 B).  As expected, the tumor 
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core had abundant of closely clustered CD68
high
 tumor cells, but the scar tissue areas of the CC-
treated and rescued mice harbored no detectable CD68
high
 GBM tumor cells (Fig. 10). 
 
Fig. 8. Efficient delivery strategies for therapeutic delivery of CC-CD68Ab and CCP to GBM mice.  
In a pilot experiment, GL261 cells (80,000) were intracranially implanted by stereotaxic injection in a 3-
month old male C57BL/6 mice on day 1 (28, 29, 42, 58). (A) The GBM mouse received only PBS (i.p.) 
from day 11, and appeared immobile and morbid on day 29. (B) The mouse was anesthetized, placed in 
the supine position, and CD68Ab-Dylight800 adduct containing 60 µg (400 pmole) of CD68 antibody 
dissolved in 30 µl of sterile PBS was applied intranasally (IN) in 3-µl drops alternately, every two 
minutes, via each nostril, and allowed to be inhaled in (schematic obtained with the authorization of 
William Frey II) (107).  The mouse was then allowed to recover and then sacrificed after six hours. (C) 
The unfixed brain of this GBM mouse was extracted post-mortem and the soft, gel-like GBM-harboring 
brain was kept with its dorsal side up on the near-IR scanner and scanned from the ventral end.  (D) Next, 




In the bright-field image, extensive hemorrhage was observed mainly in the right brain where the tumor 
was located, and near-IR dylight (800 nm) labeled, CD68(+) tumor cells (pseudo-colored green) were 
seen chiefly in the right brain and also because of metastasis it was seen also in other regions of the brain.  
Autofluorescence (700 nm) from the normal brain tissue was pseudo-colored red. (E) In long-term 
treatment-mediated survival experiments, 105 GL261 cells were intracranially implanted on day 1 as 
mentioned earlier, in each male mouse. On day 10, one randomly selected group was treated with PBS 
(Vehicle) (i.p.), a second group received CCP treatment (i.p., 2 mg per mouse in 200 µl of PBS) (ten 
mice) and a third group was IN-treated with CC-CD68Ab (120 mole per treatment in 30 µl of PBS) (eight 
mice). Results demonstrate that treatment with CCP (n = 10) and CC-CD68Ab (n = 8) caused 50-60% 









   (A)               (B) 
Fig.9. H&E staining of tumor and scar tissue region.  (A)  The GBM tumor region (showing the tumor 
core and the surrounding area) in a Vehicle-treated mouse brain. (B)  Scar tissue region (shown by a 
circle) from a CC-treated and rescued mouse. The scar tissue core areas are demarcated by arrows. Using 
parallel samples, the scar tissue regions (core and the surrounding area) and tumors were used for 
immunohistochemical and flow cytometry analyses of TAM and tumor cells. For both (A) and (B), the 
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Fig. 10.  Absence of CD68
high
 GBM tumor cells in the scar tissue area in the CC-treated and rescued 
mice.  Parallel brain sections used in Fig. 9 were immunostained with CD68 antibody. (A) GBM brains 
from the Vehicle-treated morbid mice harbored large number of closely apposed CD68high GBM tumor 
cells at the tumor core (B) The scar tissue area of the CC-treated and rescued mice lacked such CD68high 
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GBM tumor cells. (C) Graphical representation of CD68 intensity (mean ±SEM).  Scale bar: 300 µm 
(10x) and 47.62 µm (63x)  (42). 
 
3.6 Curcumin treatment and rescue is associated with a dramatic shift in the relative 
expression profiles of ARG1 and iNOS in Iba1(+) TAM. Pharmacokinetics studies show that 
the concentration of CCP-associated CC is much less than the IC50 of CCP for the GL261 cells 
(Fig. 5) (40, 44-46). Furthermore, it is estimated that inside the brain, concentrations of CC-
CD68Ab and CCP-associated CC would be even lower than the plasma concentrations of CC 
(35, 45). Still, CCP and CC-CD68Ab treatment caused GBM elimination and rescue of 50-60% 
of the GL261-implanted GBM mice. Aware of the immunotherapeutic influence of  low-doses of 
CC on the stimulation of peripheral tumor-associated immune cells like macrophages and T cells 
(18, 26, 50, 58, 72), we asked if, the major immune cells of the CNS tumors, the tumor 
associated microglia/macrophage (TAM) (Fig. 3), were influenced by CC to cause the observed 
remission of GBM mice (Fig. 8, 9 and 10) (24, 55, 60, 62, 105, 108).   
 Iba1 staining was used to identify the TAM within the GBM mass (Fig. 3) (29, 105, 108). 
We counterstained with Arginase 1 (ARG1) antibody, which is highly expressed by the 
immunosuppressive and tumor-promoting M2-like microglia (109). IHC analysis of GBM 
sections revealed that the GBM tumors and the surrounding areas (Fig. 9A) contained a large 
number of Iba1(+)/ ARG1
high
 TAM (Fig. 3A).  In sharp contrast, these Iba1(+) TAM were low in 
inducible nitric oxide synthase (iNOS
low
), which is highly expressed by the M1-like TAM (58, 
72, 110) (Fig. 3A). Next, we analyzed the relative expression of ARG1 and iNOS by Iba1(+) 
TAM present in the scar tissue and the surrounding areas (shown within a circle in Fig. 9B) in 
the brains of the CC-treated and rescued mice. A significant reduction in ARG1 along with a 
35 
 
prominent increase in iNOS expression was observed in Iba1(+) TAM present within the scar 
tissue and the surrounding  region (Fig. 3B and C).  Normalization of the staining intensity of 
ARG1 or iNOS to that for HOECHST (nuclear staining) and quantification from random fields 
of multiple mouse brains confirmed that CC-treatment and rescue was associated with an 85.1% 
decrease in ARG1 along with a 206.3% increase in iNOS in the 1ba1(+) TAM (Fig. 3B and E).    
 
(A)      Glioblastoma (Vehicle-Treated) (Died on day 29) 
        
Iba1 iNOS HOECHST Merged Iba1 ARG1 HOECHST Merged 
(B)           Scar Tissue region in RESCUED Mouse (CCP treated) 
        
Iba1 iNOS HOECHST Merged Iba1 ARG1 HOECHST Merged 
(C)        Scar Tissue region in RESCUED Mouse (CC-CD68Ab treated) 
                       
         Iba1                       iNOS             HOECHST              Merged                     Iba1                     ARG1                HOECHST             Merged 
 (D)                                                                        
 
         
 
               
           





Fig. 11.  CC treatment and rescue is associated with a dramatic shift in the relative expression of 
ARG1 and iNOS in Iba1(+) TAM.  Parallel brain sections as used in Fig. 9, harboring the GBM tumors 
from the Vehicle-treated group and scar tissues from the CC-treated and recued groups were double-
stained with Iba1 and ARG1 or iNOS antibodies. (A) the Iba1(+) TAM  of the Vehicle-treated GBM mice 
displayed weak iNOS staining and strong ARG1 staining. (B-D) The scar tissue area in the CC-treated 
and rescued groups (beyond 150 days) displayed an 85% decrease in ARG1 and a 206% increase iNOS 
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expression in the Iba1(+) TAM. The total staining intensities of ARG1 or iNOS were normalized to that 
for HOECHST. The graph represents data (mean ± S.E.M.) obtained from two mice in the Vehicle-treated 
and two in the CC-treated (one from the CCP-treated, and one from the CC-CD68Ab-treated) and rescued 
groups, using four randomly chosen brain sections containing the tumor or scar tissue from each mouse. 
(Scale bar: 47.62 µm.).  HOECHST = HOECHST33342 (42).   
 
3.7 Flow cytometry analysis in GBM or scar tissue indicates that discrete populations of 
Iba1(+) TAM are affected during CC-treatment and rescue. To corroborate the 
immunohistochemistry results, flow cytometry analysis was performed on immunostained cells 
dissociated from Vehicle-treated tumors (Fig. 9A) and CC-treated and rescued scar tissue areas 
(marked a circle in Fig. 9B). Interestingly, the GL261 tumor model has differential levels of 
hypoxia, which in turn triggers discrepancy in the phenotype of  the M2-like TAM in the GBM 
mass (111-114). Thus, it was essential for us to determine and compare the overall extent of the 
TAM activation phenotype (due to the different treatments) via flow cytometry by analyzing the 
dispersed cells from the whole tumor mass as well as dispersed cells around the tumor region. 
The dissociated cells were fixed in PFA, permeabilized with 0.1% Triton X-100 and then  
immunostained using antibodies against ARG1 and Iba1 or iNOS and Iba1. For each sample, 
events above 10
4
 forward and 10
3
 side scatter were gated, and 100,000 gated events were 
analyzed (Fig. 12 A, F).  Fluorescence from the '2° Ab only' treated cells was used to mark the 
threshold (10
4 
for FL1-A at 520 nm (green) and 10
3 
for FL2-A at 580 nm (red), confining the 2° 
Ab fluorescence to the lower left (LL) quadrant (Fig. 12 K).  The fluorescence events from 
ARG1+, Iba1(+) or iNOS+, Iba1(+) cells occurred above the secondary fluorescence in the upper 
right (UR) quadrant of FL1-A (iNOS or ARG1) and FL2-A (Iba1) (Fig. 12 B, C, G, H).  From 
these double-positive populations, the total fluorescence intensity from all the cells was recorded 
(Fig. 12 D, I) and mean fluorescence per cell was used for quantification (Fig. 12 E, J). While 
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, the Iba1(+) TAM 




 (Fig. 12 E, J). There was 
69.58% decrease in ARG1 and 154% increase in iNOS in the TAM of the CC-treated and 
rescued brains (Fig. 12 E, J).   
 
 
Fig. 12. Flow cytometry analysis of Iba1(+) TAM in GBM and scar tissue regions. Cells from GBM 
tumor (at terminal stage) or scar tissue areas (rescued mice, 150 days after GL261 implantation) were 
dispersed, fixed, permeabilized, and immunostained using iNOS, ARG1, and Iba1 antibodies.  (A and F)  
Events greater than 104 forward (FSC) and 103 side (SSC) scatter were gated. (B, C) Fluorescence 
intensity obtained beyond 104 in horizontal (green, iNOS) and 103 in vertical (red, Iba1) axes from  
Iba1(+), iNOS+ double-stained cells in each mouse was considered and the profiles of iNOS+ cells were 
obtained for the Vehicle-treated GBM (red) and scar tissue (black) cells (D). (G, H) Similarly, 
fluorescence intensity obtained above 104 in horizontal (green, ARG1) and 103 in vertical (red, Iba1) axes 
from Iba1(+), ARG1+ double-stained cells obtained from each mouse was considered and the profiles of 
ARG1
+
 cells were obtained for the Vehicle-treated GBM (red) and scar tissue (black) cells (I). (E, J) 
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Graphs showing a 69.58% decrease in ARG1 staining and a 154% increase in iNOS staining (with respect 
to Vehicle-treated) from four Vehicle-treated and three CC-treated and rescued (two CCP-treated and one 
CC-CD68 Ab-treated) mice (mean ±S.E.). (K) Events from secondary antibody-stained cells appeared 
lower than 104 in horizontal axis and below 103 in vertical axis. (L)  Similar measurements of Iba1 
fluorescence from the vertical axis for the Iba1(+), iNOS+ double-stained events  and Iba1(+), ARG1+ 
double-stained cells used in A-E and F-J, show a corresponding decrease in Iba1 fluorescence in the 
ARG1+ TAM (73.92%) and an increase in Iba1 fluorescence (184%) in iNOS+ TAM, with respect to the 
Vehicle-treated for each group (mean ±SEM). (M) No significant difference in total Iba1 fluorescent 
TAM between double-positive cells from the Vehicle-treated GBM tissue and the CC-rescued scar tissue 
(42).  
  
 The mean Iba1 fluorescence per double-stained cell (ARG1+ or iNOS+) was also 
significantly different between the two groups. While the mean Iba1 fluorescence intensity in the 
ARG1+ TAM in the scar tissue area of the rescued mice was 73.92% less, the mean Iba1 
fluorescence in the iNOS+ cells in the scar tissue area was 184%  higher (Fig. 12 l).  Thus, CC 
treatment and rescue caused a parallel decrease in both ARG1 and Iba1 fluorescence and a 
parallel increase in iNOS and Iba1 fluorescence in the TAMs. However, the mean Iba1 intensity 
did not significantly alter between the two groups (iNOS+, Iba1(+) and ARG1+, Iba1(+) cells) 
(Fig. 12M).  Since Iba1 is a signature of TAM activation, this supported the possibility that CC 
treatment and rescue was responsible for the silencing of one group of ARG1+ TAM (M2-like) 
and the concomitant induction of a different set of iNOS+ TAM (M1-like). 
3.8 CC-treated and rescue of GBM mice was associated with a pronounced inhibition of 
activated-STAT3 and IL10, and dramatic induction of activated-NF-kB (p65), activated-
STAT1 and IL12 in the TAM.  Based on earlier reports by us and others (50, 72, 115), we 
expected that CC-induced mechanism of the observed M2 to M1 repolarization of the TAM 
would involve inhibition of STAT3 (Fig. 13) in the Iba1(+) TAM which would in turn prompt 
suppression of  IL10 (Fig. 16) and, induction of P-STAT1 (Fig. 14) and IL12 (Fig. 13) in these 
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TAM (85, 116-118). Activated-STAT1 would induce the observed iNOS expression (Fig.11 and 
12), thus causing increased nitric oxide (NO) release from the TAM (69, 72).   
 We observed via IHC that the TAM of the GBM tumor in the Vehicle-treated morbid 
mice harbored high levels of activated STAT3 (P-Y
705
-STAT3 or P-STAT3) (Fig. 13 A and B), 
but the scar tissue sections from the CC-treated and rescued mice displayed a 98% suppression 
of P-STAT3 (fig. 13 A and B) in the Iba1(+) TAM.  The overall suppression of P-STAT3 was 
due to a combination of suppressed STAT3 expression (Fig. 13 C) and inhibited STAT3 
phosphorylation (Fig. 13 D). 
 
Fig. 13. The TAM (Iba1(+)) in the CCP-treated and rescued mice displayed a dramatic inhibition of 
activated STAT3.  Brain sections parallel to those used in Fig. 11 were immunostained to assess the 
levels of STAT3 and P-Tyr705-STAT3 (activated) in the Iba1(+) TAM. (A upper and lower rows) and 
(B) The TAM of the Vehicle-treated mice harbored a elevated level of activated (P-Y705-STAT3), which 
was suppressed by 98% in the scar tissue TAM of the CCP-treated and rescued mice. This overall down-
regulation of P-STAT3 was a result of inhibition of STAT3 expression (STAT3 normalized to 
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HOECHST) (C) and STAT3 activation (P-STAT3 normalized to STAT3) (D). Four sections per mouse 
per group were used for imaging and analysis. Data (mean ± SEM) were graphically presented as 
obtained from Vehicle-treated mice (n=3), and CCP-treated and rescued mice (n=3). HOECHST = 
HOECHST33342. (Scale bar:  47.62 µm). 
  
 Suppression of activated-STAT3 is known to cause induction of activated-STAT1 to 
promote the M1-like phenotype in the TAM (72, 115, 119). Consistent with this observation, the 
Iba1(+)
 
TAM in the scar tissue from the CC-treated and rescued mice showed a 591%  increase 
in activated STAT1 (P-Tyr
701
-STAT1 normalized to total STAT1) (Fig. 14 A, B, C).  
Additionally a 775%  induction in STAT1 (Fig. 14 A, B, D), resulted in an overall 5134% 
increase in activated (P-STAT1) in the TAM of the CC-treated and rescued mice (Fig. 14 A, B, 
E). 
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Fig 14.  Induced STAT1 expression and activation in Iba1(+) TAM in the scar tissue region of the 
CC-treated and rescued mice.  Brain sections parallel to those used in Fig. 13 were used to determine 
the levels of STAT1 and P-Tyr701-STAT1 (activated) in the tumor and scar tissue areas of the Vehicle-
treated and CC-treated and rescued mice, respectively. (A-C)  Relative to that in the Vehicle group, a 
591% increase in P-STAT1/STAT1 (activation) was observed in the scar tissue Iba1(+) TAM. (A, B, and 
D)  Concurrently, a 775% induction in STAT1 was observed in the scar tissue Iba1(+) TAM.  (A, B, and 
E)  This resulted in an overall increase of 5134% in P-STAT1 in the scar tissue Iba1(+) TAM. Five 
sections per mouse per group were used for imaging and analysis. Data were graphically presented as 
mean ± SEM.  HOECHST = HOECHST33342. Scale bar:  47.62 µm (42).   
  
 Earlier studies performed in macrophages postulate that co-activated (phosphorylated) 
NF-kB (p65) and STAT1 cooperate by binding to appropriate enhancer elements to stimulate the 
iNOS gene (120, 121). To effect such a change, CC treatment should cause phosphorylation-
mediated activation of both of these two transcription factors in the TAM of the CC-treated and 
rescued mice. 
 As expected, the Iba1(+) TAM in the scar tissue of the CC-treated and rescued mice 
showed an 85%  increase in activated p65 NF-kB (P-Ser
276
-p65 normalized to total p65 NF-kB) 
compared to that in the Vehicle-treated tumor sections (Fig. 15 A, B, C).  In parallel, a 300% 
augmentation in p65 NF-kB expression was observed in the Iba1(+) scar tissue TAM (Fig. 15 
D), which resulted in a net increase of 642% in P-p65 NF-kB in the scar tissue TAM over that of 
the TAM of the Vehicle-treated tumor (Fig. 15 E).                   
 Suppression of  P-STAT3, along with activation of the STAT1 cascade, is also known to 
cause a decrease in TAM-associated IL10 (M2-like TAM marker) expression along with 
increased expression of IL12 (M1-like TAM marker) (72, 122). Based on these findings, we 
wanted to verify if the observed CC-mediated M2M1 polarization (Fig. 10 and 11) could be 




(M1) phenotype. As 
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TAM, whereas, the TAM in the scar tissue area of the CC-treated and rescued mice showed a 
91% decrease in IL10 and a 300% increase in IL12 expression (Fig. 16). 
































Fig. 15. Induced p65 NF-kB expression and activation in the Iba1(+) TAM in the scar tissue region 
of the CC-treated and rescued mice. Brain sections parallel to those used in Fig. 14 (from three 
Vehicle-treated  morbid mice, and three CC-treated and rescued mice- one CCP-treated and one CC-
CD68Ab-treated) were used to assess the levels of p65 NF-kB and P-Ser276-p65 NF-kB (activated) in the 
Iba1(+) TAM.  (A) The Vehicle-treated mice showed sparse levels of p65 NF-kB and P-Ser276-p65 NF-kB 
(top row of (A)). The TAM of CC-treated and rescued mice (bottom row of (A)) showed an 85% increase 
P-p65 NF-kB with respect to p65 NF-kB (activation) (B, C), a 300% induction in p65 NF-kB, thus 
resulting in (E) a 642% net increase in P-p65 NF-kB with respect to that of the Vehicle-treated group. 
Five sections per mouse were used for imaging and analysis. Data were graphically represented as mean ± 




3.9 CCP treatment-associated recruitment of activated NK cells into the GBM tumor: 
Expression of IL12 (in this case derived from the M1-like TAM) (Fig. 16) is known to cause 
intra-tumor recruitment of activated NK cells (67, 69, 72, 123). Immunostaining for NKp46, 
which is a marker for activated NK cells (58, 72, 124), we observed very few activated NK cells 
in the GBM tumor harbored by the Vehicle-treated mice. In sharp contrast, the scar tissue region 
of CCP-treated and rescued mice (Fig. 9) exhibited a 800% increase in NKp46 fluorescence 
compared to the Vehicle-treated (Fig. 17 A and B). Along with M1-like TAM, activated NK 
cells are known to be highly tumoricidal and could responsible for GBM remission in the CC-








, whereas the TAM in the 




. Brain sections parallel to those 
used in Fig. 15, harboring the GBM tumor (Vehicle-treated) and scar tissue (CCP-treated and rescued) 
were triple-stained with Iba1, IL10 and IL12 antibodies. The TAM in the GBM tissue in Vehicle-treated 
mice display high levels of IL10 and low levels of IL12 (A, upper row), whereas the scar tissue from the 
CCP-treated and rescued mice displayed IL10low and IL12high TAM  (A, lower row, B and C). The 
quantified graphs (mean ± S.E.M.) showed a 91% decrease in IL10 and a 300% increase in IL12 
following CCP-treatment and rescue (n=3 per group, with four randomly chosen brain sections from each 
mouse). (Scale bar: 47.62 µm). HOECHST = HOECHST33342 (73).    
 
Furthermore, it has been shown that activated NK cells cause expression and release of 
IFNγ, which is a potent activator of M1 phenotype (115, 117, 127, 128). In light of these studies, 
we next investigated the direct role of the activated NK cells in the observed CC-evoked 
M2M1 repolarization of TAM and in GBM elimination. To accomplish this, we used a short-
term regimen of CCP treatment, which was insufficient to cause complete elimination of the 
GBM. The NK cell surface antigen NK1.1 (PK136) is known to be a selective NK cell marker in 
C57BL/6 mice (129-131). So, one set of randomly chosen GBM mice was first injected with the 
NK1.1 antibody (NK1.1Ab) to eliminate the peripheral NK cells as demonstrated earlier (132). 
Subsequently, from the next day, CCP treatment was conducted on the NK1.1Ab-treated set and 
also on one of two (mouse IgG, MS)-treated groups for five days. The second (mouse IgG, MS)-
treated (Vehicle) group received PBS for five days. Twenty-four hours after the fifth day of 
treatment (i.e. on day 17th from tumor cell implantation), animals in all three groups were 






Fig. 17.  CCP-treatment and rescue of GBM mice is associated with the scar tissue rescued mice 
harboring activated natural killer (NK) cells. Brain sections parallel to those used in Fig.16, harboring 
the GBM tumor (Vehicle-treated) and scar tissue (CCP-treated and rescued) were probed via IHC with 
the activated NK cell-specific NKp46 antibody. (A) and (B) The Vehicle-treated tumor tissue displayed 
sparse NKp46 stain, the scar tissue sections obtained from the CCP-treated and rescued mice show an 
800% increase in NKp46-staining (mean ± S.E.M.). (n=3 per group, with four randomly chosen brain 








Fig. 18. GBM tumor generation by GL261 implantation on day 1, peripheral treatment with mouse 
IgG (MS) or the NK-cell-neutralizing NK1.1 antibody on day 11, followed by a regimen of Vehicle 
(or CCP) treatment for five days yielded tumors in all the group on day 17. (A) As shown by near-IR 
scanning,  intracranial implantation of 105 GL261 cells in the mice on day 1 resulted in the formation of 
GBM tumor in all the groups on day 17. A representative tumor of a Vehicle-treated mouse is shown 
here. (B) On day 11, GBM-mice (n=14) were randomly divided into three groups: 'Vehicle' (n=5), 'CCP' 
(n=5), and 'CCP+NK1.1' (n=4). The mice in the CCP+NK1.1 group received i.p. injection of the NK cell-
neutralizing mouse anti-NK1.1 antibody (100 µg/mouse) (69). Mice of the other two groups received 
Mouse Ig. On day 12, each mouse received i.p. injections of sterile PBS (Vehicle group) or CCP (2 mg/ 
mouse/day) for the CCP and CCP+NK1.1 groups for five days. On day 17, all mice were sacrificed.  (C) 
Forward- versus side-scatter plot showing the population of cells chosen for the analysis of fluorescence. 
(D) The day-17 GBM tumors from the mice were isolated, gently dissociated and the cells were subjected 
to immunostaining for CD68 and Iba1 followed by flow cytometry analysis to confirm the presence of 
established GBM tumors (29, 42, 58). Two segregated populations of CD68(+) cells were identified.The 
larger population (presumably GBM cells) were Iba1(-) and CD68high, whereas the Iba1(+) but CD68low 
cells were expected to be the TAM (42, 58). (E and F) The Iba1(-)/CD68high (GBM cells) in the GBM 
samples showed 680% higher integrated CD68 fluorescence (fluorescence per cell in arbitrary units X 
number of events) x108 relative to the Iba1(+)/CD68low (TAM cells) (p=1.7x10-4). The graph represents 
mean ± SEM acquired from the analysis of the GBM mice (n = 6) (73). 
 
3.10 GL261 implantation on day 1 results in a large brain tumors on day 17, which harbors 
CD68
high
, Iba1(-) tumor cells and CD68
low
, Iba1(+) TAM. We have shown earlier, that within 
the tumor mass, GBM cells were CD68
high
, whereas the TAM express relatively low levels of 
CD68 (CD68
low
)  (Fig. 3) (42, 58). Implantation of 10
5
 GL261 cells on day 1 resulted in tumors 
in all the mice of all the groups on day 17, especially large tumors in the Vehicle-treated mice 
(Fig. 18 A). Following dissociation of these tumor cells by mild trypsinization and staining for 
CD68 and Iba1, the cells were analyzed by flow cytometry in the high forward- and side-scatter 
range (Fig. 18 C) (42, 58, 72). Two clearly segregated populations of CD68(+) cells were 
identified (Fig. 18 D).  The larger population of presumably GBM tumor cells was Iba1(-) and 
CD68
high
, whereas the Iba1(+) but CD68
low
 cells were expected to be the TAM (Fig. 18 D-F). 
The integrated CD68 fluorescence (IF) (mean fluorescence per cell x total number of cells in the 
population) in the CD68
high
 population was 680% higher than that in the CD68
low
 population 
(Fig. 18 E and F). 
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3.11 CCP treatment triggers NK cell recruitment into the GBM tumor and peripheral 
NK1.1Ab pre-treatment abrogates it. GL261-implanted GBM mice were peripherally infused 
for five days with Vehicle, or CCP without NK1.1Ab pretreatment (CCP) or with NK1.1Ab pre-
treatment (CCP+NK1.1) (Fig. 19 A). These treatments were sufficient to cause a 200% increase 
in activated (NKp46(+)) NK cells in the GBM tumor of the CCP- but not CCP+NK1.1Ab-treated 
mice (Fig. 19 B and C). Virtually no NKp46(+) cells were detected in the NK1.1Ab-pretreated 
mice (Fig. 19 B, third row and C). Concurrent flow cytometry analysis confirmed that CCP-
treatment elicits a 190% increase in NKp46 IF, revealing recruitment of activated NK cells into 
the GBM tumor mass. This CCP-triggered NK cell infiltration was abrogated in the NK1.1Ab-





































Fig. 19. 5-day CCP treatment is associated with intra-tumor recruitment of activated NK cells, 
which is eliminated by peripheral injection with the NK cell-neutralizing NK1.1 antibody 
(NK1.1Ab) in mice. (A) After intracranial implantation of 10
5






(n=17) were randomly separated into three groups: 'Vehicle' (n=5), 'CCP' (n=5), 'CCP+NK1.1' (n=4) and 
'NK1.1' (n=3). On day 11, the mice of the 'CCP+NK1.1' and 'NK1.1' groups were injected with the 
NK1.1Ab (100 µg/mouse), whereas the other two groups received mouse IgG (100 µg/mouse) (i.p.). On 
day 12, each mouse received either CCP (2 mg/ mouse/day in 200 µl sterile PBS) for the CCP and 
CCP+NK1.1 groups or PBS for the 'Vehicle' and 'NK1.1' groups for five days. On day 17, all mice were 
sacrificed and the GBM tumor in each mouse (Fig. 18) was divided into two parts and processed for IHC 
(fixed and sectioned) and flow cytometry (dispersed into single cell suspensions by trypsinization and 
then fixed), respectively. (B and C) IHC: Four randomly chosen GBM-containing brain sections per 
mouse from each group were stained with the NKp46 antibody. The Vehicle-treated mice displayed very 
weak and sparse NKp46 staining (B top row and C), whereas the CCP-treated showed a 200% increase in 
NKp46 fluorescence (B middle row and C). This CCP-evoked presence of NK46+ NK cells was nearly 
eliminated in the NK1.1Ab-treated mice (B bottom row and C) (*p = 1.2 x 10-8 CCP versus Vehicle-
treated; ∆ p = 7.3x10-9 CCP versus CCP+NK1.1; **p = 1.0x10-3 CCP+NK1.1 versus Vehicle-treated) 
(Scale bar: 47.62 µm). (D-F) Flow cytometry: CCP-treated samples displayed a 190% increase in NKp46 
IF (*p = 0.02, CCP versus Vehicle).  The NKp46 IF was nearly eliminated in the CCP+NK1.1 mice (F, ∆ 
p = 0.04, CCP+NK1.1 versus CCP; **p = 5.0x10-3, CCP+NK1.1 versus Vehicle-treated). Data (mean ± 
S.E.M.) obtained from Vehicle (n=4), CCP (n=4), and CCP+NK1.1 (n=4). Integrated fluorescence (IF) = 
mean fluorescence per cell  X total number of cells (events) in a segregated population. (D, E) The 
NKp46(+) events (NK cells) were virtually eliminated in the NK1.1 samples (73). 
  
 Because of the negligible presence of NKp46(+) NK cells in the 'Vehicle' group and since 
it is known that the blood-brain barrier (BBB) obstructs the intra-brain entry of antibodies, it is 
most likely that the peripheral injection of the NK1.1Ab depleted only peripheral NK cells in the 
'CCP+NK1.1' group to annul the CCP-induced intra-GBM infiltration of these cells (133).  
 As a negative control for CCP and the proof of NK1.1-mediated NK cell neutralization, 
flow cytometry analysis for NKp46 staining for NK1.1 mice exhibited negligible number of 
intra-GBM NKp46(+) NK cells, similar to the NKp46 profile of the CCP+NK1.1 group (Fig. 2D 
and E). This further demonstrated the selective specificity of the peripherally administered 
NK1.1Ab towards the NKp46(+) NK cells (present in the peripheral system) to induce their 




3.12 Intra-GBM recruitment of NK cells is eliminated upon neutralization of peripheral 
IL12 signaling using an IL12 antibody. Similar to the complete blockage of intra-GBM 
recruitment of the NK cells in the GBM mice which received peripheral injection of the NK1.1 
antibody (Fig. 19), blocking IL12-mediated NK cell signaling by peripheral infusion with an 
IL12 antibody almost eliminated activated NK cell infiltration into the GBM tumor (Fig. 20 A-
C) (69, 72). This observation confirmed the role of peripheral IL12. which is possibly playing a 
major role in the activation and/or recruitment of NK cells into the GBM tumor (67, 72). 
 One of the major source of this peripheral IL12 is the M1-like macrophages, which can 
also get recruited to the tumor site to mount an antitumor immune response (69, 81, 134-136). 
However, we did not observe the presence of macrophages in the Vehicle-treated GBM brain 
(Fig. 3). So next, we wanted to determine the composition of the TAM (relative proportion of 
glioma associated-microglia and macrophages) after CCP treatment and further wanted to verify 
if CCP is causing M1-like macrophage recruitment into the GBM. 
3.13 CCP treatment causes NK cell-independent recruitment of activated macrophages into 
GBM. As expected, we observed recruitment of activated macrophages (50-60% of the TAM) 
into the GBM brain equally in both CCP-treated and CCP+NK1.1Ab-treated mice, which ruled 
out any role of the peripheral NK cells in the intra-GBM macrophage recruitment (Fig. 21). The 
activated macrophages were detected by selective immunostaining with the RM0028-11H3 
antibody (Fig. 3, 21) (137). Iba1 staining, however, stained both activated microglia and 
macrophages, as verified from IHC staining of peripheral tumors (HPV+ TC1 tumors) (Fig. 3, 
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Fig. 20. Five-day CCP treatment causes intra-tumor recruitment of activated NK cells, which is 
eliminated in mice treated peripherally with an IL12 Ab. After intracranial implantation of 105 GL261 
cells on day 1, the GBM-mice (n=9) were randomly separated into three groups: 'Vehicle' (n=3), 'CCP' 
(n=3), and 'CCP+IL12Ab' (n=3). On day 11 and day 14, the CCP+IL12Ab group received NK cell-
neutralizing rat anti-IL12p40 Ab (100 µg/mouse/day), whereas the other two groups received rat IgG (100 
µg/mouse) (i.p.). On day 12, each mouse was treated with CCP (2 mg/ mouse/day in 200 µl PBS) (i.p.) 
for the CCP and CCP+IL12Ab groups and sterile PBS (i.p.) for the “Vehicle” group for five days. On day 
17, all mice were sacrificed and the dispersed cells were immunostained for flow cytometry analysis. 
CCP-treated mice display a 270% increase in integrated NKp46 fluorescence (370% of Vehicle-treated) 
(A, B, C; *p = 0.01, CCP versus Vehicle). The NKp46 fluorescence was nearly absent in the GBM 
samples from the CCP+IL12Ab group ((A, B, C; ∆ p = 4.4 x10-4, CCP+IL12Ab versus CCP; **p = 
2.7x10-3, CCP+IL12Ab versus Vehicle-treated). The graphs represent data (mean ± S.E.M.) obtained 
from Vehicle (n=3), CCP (n=3), and CCP+IL12Ab (n=3). Integrated fluorescence = average fluorescence 

































































Fig. 21. CCP treatment triggers NK cell-independent, intra-GBM recruitment of peripheral 
macrophages. GBM Brain sections parallel to those used in Fig.19 were used to evaluate the possibility 
of intra-tumor recruitment of peripheral macrophages (macrophage specific marker RM0029-11H3(+) 
cells) upon CCP-treatment. (A) The GBM sections from the Vehicle-treated group harbored chiefly 
tumor-associated microglia (Iba1(+), RM0029-11H3(-), green) and a few macrophages (Iba1(+), 
RM0029-11H3(+), yellow) (first row), whereas the GBM tumors of the CCP (second row) and 




RM0029-11H3(+)). Double-staining (Iba1(+), RM0029-11H3(+)) of peripheral tumors (HPV+ TC1 
tumors, a positive control) (fourth row) confirmed that the tumor-associated TAM observed in the GBM 
sections were macrophages from the periphery. (B) CCP-treatment induced a 53% increase in the number 
of recruited intra-tumor macrophages (yellow) (*p = 7.8 x 10-4 Vehicle versus CCP). The CCP+NK1.1 
group also showed a 60% increase in the number of recruited intra-GBM macrophages (**p = 3x10-3 
Vehicle versus CCP+NK1.1). Three sections per mouse were used for quantifications and the data (mean 
± S.E.M.) acquired from Vehicle-treated (n = 4), CCP-treated (n = 4), and CCP+NK1.1-treated groups (n 
= 4). (Scale bar:  47.62 µm) (73). 
 
3.14 CCP treatment causes a dramatic suppression of STAT3 in TAM, which is partially 
reversed in the NK1.1Ab-treated mice. We next tested the contribution of the activated NK 
cells in CCP-induced inhibition of activated-STAT3 (M2 marker) in the TAM (tumor-associated 
resident microglia and recruited macrophages) of the GBM mice. While, the five-day Vehicle-
treated mice showed high levels of P-STAT3 as well as STAT3 in the Iba1(+) TAM, CCP 
treatment induced a net 88.5% decrease in P-STAT3, and this suppression was only by 61% in 
the CCP+NK1.1Ab-treated GBM mice (Fig. 22 A and B). Thus it is likely that the difference 
(88.5-61% = 27.5%) in P-STAT3 inhibition was due to the recruited NK cells (Fig. 19). The 
CCP-evoked 88.5% suppression of P-STAT3 was the combined effect of an inhibition of STAT3 
(expression) (79%) and suppression of P-STAT3 (activation) (69%) in the Iba1(+) TAM (Fig. 22 
A-D). Both STAT3 as well P-STAT3 levels were partially re-established in the Iba1(+) TAM in 
the GBM mice receiving CCP+NK1.1 (Fig 22. A-D).   
 As discussed earlier, inhibition of activated STAT3 in the TAM is associated with 
induction of activated STAT1 (M1 marker). So next we investigated the role of activated NK 




Fig. 22. The elimination of intra-GBM recruitment of activated NK cells by peripheral injection of 
NK1.1 Ab partially reverts the CCP-mediated suppression of activated STAT3 in the TAM. GBM 
Brain sections parallel to those used in Fig. 21 from the three groups were used to evaluate the levels of 
STAT3 and activated STAT3 (P-Y705-STAT3) (P-STAT3) in the Iba1(+) TAM. (A) The TAM of the 
GBM sections from the Vehicle-treated mice showed high levels of STAT3 and P-STAT3 (top row), 
whereas the CCP-treated mice showed an 88.5% decrease in P-STAT3 (normalized to HOECHST) in the 
TAM (*p = 5.1 x 10-5 versus Vehicle) and this CCP-evoked suppression was only by 61% in TAM from 
the CCP+NK1.1 group (∆ p = 5.9 x 10-3, CCP+NK1.1 versus CCP-treated) (B). The CCP-evoked 88.5% 
suppression of P-STAT3 in the TAM was the consequence of a 79% decrease in STAT3 (normalized to 
HOECHST) (only 68% in the CCP+NK1.1 mice) (C), and a 68% decrease P-STAT3 (normalized to 
STAT3) (only 48% in CCP+NK1.1) (P-STAT3 normalized to STAT3) (**p = 1.2x10-4 Vehicle versus 
CCP+NK1.1) (D). Three random GBM sections per mouse were used for analysis and the graphs 
represent data (mean ± S.E.M.) obtained from Vehicle (n=4), CCP (n=4), and CCP+NK1.1 (n=4). (Scale 





3.15 CCP treatment prompts a dramatic increase in P-STAT1, which is partially reversed 
in the NK1.1Ab-treated mice. As expected, the Vehicle-treated GBM mice displayed low 
levels of STAT1 and sparse levels of P-STAT1. Whereas, the CCP-treated GBM mice displayed 
a 1286% increase in P-STAT1 in the Iba1(+) TAM.  In contrast, the NK1.1Ab+CCP-treated 
mice showed only a 300% increase in P-STAT1 (Fig. 23 A and B). Thus, the difference in P-
STAT1 induction (1286%-300% = 986%) was likely due to the recruited NK cells. The overall 
CCP-evoked increase in P-STAT1 was due to a combination of STAT1 induction (Fig. 23 C) 
and STAT1 activation (P-STAT1 normalized to STAT1) (Fig. 23 D) and similar to the STAT3 
data (Fig. 22), both of these changes were partially reversed in the NK1.1Ab+CCP-injected 
GBM mice. 





















































Fig. 23.  Elimination of intra-GBM recruitment of activated NK cells partially reverses the CCP-
mediated induction and activation of STAT1 in the TAM. GBM Brain sections parallel to those used 
in Fig. 22 from the three groups were used to evaluate the levels of STAT1 and activated STAT1 (P-
STAT1) in the Iba1(+) TAM. (A) The TAM of the Vehicle-treated mice showed low levels of STAT1 
(red) and P-STAT1 (purple) in the Iba1(+) (green) cells (First row and B), but a 1286% overall increase in 
P-STAT1 was observed in the TAM of the CCP-treated GBM sections (Second row and B) (*p = 2.3 x 
10-4, Vehicle versus CCP). This CCP-evoked increase in P-STAT1 was only 300% in the TAM of the 
CCP+NK1.1 group (Third row and B) (∆ p = 0.04, CCP versus CCP+NK1.1).  The CCP-evoked increase 
in P-STAT1 was the outcome of a 300% induction in STAT1 (only 194% increase in the CCP+NK1.1 
sections) (A, C), and a 423% increase of P-STAT1 with respect to STAT1 (activation) (only 206% 
activation in the CCP+NK1.1 group) (**p = 2.9x10
-4 , Vehicle versus CCP+NK1.1) (A, D).  Three sections 
per mouse were used for analysis and the graph represents data (mean ± S.E.M.) obtained from GBM 
mice treated with Vehicle (n=4), CCP (n=4), and CCP+NK1.1 (n=3). (Scale bar: 47.62 µm) (73). 
 
3.16 Pretreatment with the NK1.1Ab partially blocks the CCP-evoked M2M1 
repolarization. As discussed earlier, the CCP-triggered inhibition in activated STAT3 (P-
STAT3)  and induction in activated STAT1 (P-STAT1) in the Iba1(+) TAM (Fig. 22 and 23) are 
expected to have their downstream effects on the expression of the cytokines IL10 and IL12, 
respectively. As mentioned earlier, the activation of the transcription factor STAT3 is known to 
induce both ARG1 and IL10, whereas the activation of STAT1 has been reported to cause iNOS 
and IL12 expression (72, 115, 119). In other words, as observed from Fig. 22 and 23, we expect a 
concurrent switch in polarity of the M2-like TAM to the M1 phenotype due the 5-day CCP 
treatment of the GBM mice. Indeed, as demonstrated via flow cytometry analysis, the CCP-
induced inhibition in activated STAT3 was simultaneously associated with an 80% suppression 
of ARG1 staining in the Iba1(+) TAM (Fig. 24A i, ii, v). Only a 60% decrease in ARG1 was 
observed in the NK1.1Ab+CCP-treated mice (Fig. 24A iii).  Therefore, the difference (80%-60% 
= 20%) was possibly due to the effect of the recruited NK cells. A parallel 293% enhancement in 
iNOS was also found in the TAM  (Fig. 24B i, ii, v).  In contrast, the NK1.1Ab+CCP-treated 
mice showed only an 89% increase in iNOS IF (Fig. 24B iii and v). Thus, the difference (293% - 
89% = 204%) was likely to be due to the intra-GBM recruitment of the activated NK cells.   
57 
 
Triple-staining (IHC) with Iba1, AG1 and iNOS antibodies (Fig. 25) further corroborated 
the flow cytometry analysis of Fig.24. 
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Fig. 24. Peripheral injection of the GBM mice with a NK cell-neutralizing antibody NK1.1 partially 
blocks the CCP-mediated-M2 to M1 repolarization of the TAM.  (A) The dispersed Iba1(+) TAM in 
the CCP-treated GBM mice exhibited an 80% decrease in ARG1 IF with respect to the Vehicle-treated 
group (*p = 0.01, Vehicle versus CCP) and this decrease was only 60% in the CCP+NK1.1 mice ((∆ p = 
0.03, CCP versus CCP+NK1.1; **p = 0.02, Vehicle versus CCP+NK1.1) (A i-v). In comparison, with 
respect to the iNOS IF values in the Vehicle-treated group, the Iba1(+) TAM in the other two groups 
showed an 293% increase (in the CCP-treated group) (*p = 0.004, CCP versus Vehicle) and an 89% 
increase (in the CCP+NK1.1-treated group) (∆ p = 0.014 CCP+NK1.1 versus CCP; **p = 0.04, Vehicle 
versus CCP+NK1.1) (B i-v).  The graphs represent mean ± S.E.M for iNOS/ARG1 obtained from Vehicle 
(n=4), CCP (n=4), and CCP+NK1.1 (n=3) mice.  (C-F)  The Iba1(+) TAM also exhibited a 92% decrease 
IL10 IF in the CCP-treated (*p = 8.7x10-6, CCP versus Vehicle) while only a 65% decrease in the 
CCP+NK1.1-treated group (∆ p = 0.03, CCP+NK1.1 versus CCP; **p = 5.0x10-3, Vehicle versus 
CCP+NK1.1) (C i - iv and E).  The Iba1(+) TAM displayed a 445% increase in IL12 IF in the CCP-
treated mice (*p = 0.01, CCP versus Vehicle) and a 69% increase in the CCP+NK1.1 samples (∆ p = 
0.01, CCP+NK1.1 versus CCP; **p = 0.04, Vehicle versus CCP+NK1.1) (D i-iv and F). The graphs 
represent data (mean ± S.E.M.) obtained from Vehicle (n=4), CCP (n=4), and CCP+NK1.1 (n=3) mice 
(73).   
 
In addition to this repolarization, using flow cytometry, the IF measurements from 
another set of M2 and M1 phenotypic marker, IL10 and IL12, respectively was performed (72, 
138, 139). The results showed high IL10 staining of the Iba1(+) TAM in the Vehicle-treated 
GBM mice, which was inhibited by 92% in the CCP-treated GBM mice (Fig. 24 C i, ii, iv and 
E).  Whereas. the NK1.1Ab+CCP-treated mice showed only a 65% reduction in IL10 IF (Fig. 24 
C iii and E). Thus the difference (92%-65% = 27%) was likely due to the recruited NK cells 
within the GBM. 
The high IL10 expression in the Iba1(+) TAM was associated with a very low level of 
IL12 expression in the Vehicle-treated GBM mice. But, the IL12 IF was increased by 445% in 
the CCP-treated GBM mice (Fig. 24 D i, ii, iv, and F). On the contrary, the NK1.1Ab+CCP-
treated GBM mice showed only a 69% increment in IL12 IF (Fig. 24D iii and F). So, the 
difference in IL12 expression (445%-69% = 376%) was likely due the recruited NK cells. 
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Additionally, immunostaining with Iba1, IL10 and IL12 antibodies (Fig. 26), validated 
the flow cytometry data shown in Fig. 24. 
Thus, it is highly likely that the recruited NK cells are responsible for the enhancement of 
the CCP-induced M1 phenotype of the TAM. So, next, we investigated the role of M1 TAM and 
activated NK cells in the elimination of GBM cells and GBM stem cells (24, 60, 62, 124, 126).  
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Fig. 25. Neutralization of intra-GBM recruitment of activated NK cell partially reverses the CCP-




groups were triple-stained with Iba1 (green), iNOS (red) and ARG1 (purple) antibodies. (A) The Vehicle-
treated GBM sections displayed weak iNOS staining but strong ARG1 staining in the Iba1(+) TAM (A, 
top row). In contrast, the CCP-treated mice presented a 58% decrease in ARG1 (*p= 2.5 x 10-6 CCP 
versus Vehicle). This CCP-evoked suppression in ARG1 was only 35% in the CCP+NK1.1 sections (∆ 
p=5.6x10-7, CCP+NK1.1 versus CCP; **p=3x10-4, CCP+NK1.1 versus Vehicle) (A, middle row, and B).  
In contrast, the Iba1(+) TAM in the CCP-treated mice showed a 212% increase in iNOS (*p= 6.2x10-7, 
CCP versus Vehicle) and this CCP-evoked increase in iNOS was only 147% in the CCP+NK1.1 mice (∆ 
p=1.1x10-4, CCP+NK1.1 versus CCP; **p=7.6x10-5, CCP+NK1.1 versus Vehicle) (A, lowest row, and 
C).  Four sections per mouse were used for imaging and the graphs represent mean ± S.E.M. obtained 
from Vehicle (n=4), CCP (n=4), and CCP+NK1.1 (n=3). (Scale bar: 47.62 µm) (73). 
 
 

































Fig. 26. Abrogation of the intra-GBM recruitment of activated NK cell partially reverses the CCP-
mediated suppression of IL10 and induction of IL12 in TAM. GBM Brain sections parallel to those 
used in Fig. 22 from the three groups were triple-stained with antibodies against Iba1 (green), IL12 (red), 
and IL10 (purple). Sections from Vehicle-treated mice showed strong IL10 expression in the Iba1(+) 
TAM (A first row), which was suppressed by 83% in the CCP-treated mice (*p = 9.1x10-8, CCP versus 
Vehicle) (A, second row and B), but this CCP-evoked suppression of IL10 was only 45% in the 
CCP+NK1.1 sections (∆ p = 8.3x10-8, CCP+NK1.1 versus CCP; **p=2.7x10-5, CCP+NK1.1 versus 
Vehicle) (A third row and B).  In contrast, IL12 expression in the Iba1(+) cells was very low in the 
sections from the Vehicle-treated mice (A first row), but it increased by 439% in the CCP-treated mice 
(*p = 1.3x10-10, CCP versus Vehicle) (A second row and C), and this increase was only 277% in the 
CCP+NK1.1 mice (∆ p= 9.3x10-6, CCP+NK1.1 versus CCP; **p=4.6x10-7, CCP+NK1.1 versus Vehicle) 
(A third row and C). Four sections per mouse from Vehicle (n=4), CCP (n=4), and CCP+NK1.1 (n=3) 
mice were used for imaging and each graph represents mean ± S.E.M. (Scale bar: 47.62 µm) (73). 
 
3.17 NK1.1Ab treatment partially reverses CCP-evoked elimination of CD133(+) and 
SOX2(+) GBM stem cells and caspase-3 activation in CD68
high
 GBM cells. In order to study 
the role of NK cells in the CCP-evoked elimination of GBM,  IHC as well as flow cytometry 
analysis of GBM stem cell marker CD133 was performed (58, 140). The results revealed a 72% 
reduction in CD133(+) staining in IHC in the CCP-treated GBM mice. Whereas, CCP+NK1.1-
treated GBM mice showed only a 41% decrease in CD133 staining (Fig. 27 A-E). 
Corroboratively, flow cytometry demonstrated an 81% suppression of CD133(+) GBM stem cell 
IF in the CCP-treated, but only a 32% decrease in the CCP+NK1.1-treated mice (Fig. 27 C and 
D). So, the difference between the CCP and CCP+NK1.1 groups (81%-32% = 49%) was likely 
due to the intra-GBM recruited NK cells. 
The GBM stem cells are also known to be SOX2 positive (13, 58), and SOX2 staining 
and IHC analysis from parallel sections (Fig. 28) corroborated data presented in Fig. 27. 
 Although the 5-day CCP treatment triggered a decrease in tumor load in the GBM mice, 
and this decrease was partly reverted in the NK cell neutralized mice, these alterations in tumor 
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load were not significant to each other (data not shown). interestingly, GBM tumor harbors 
necrotic tissues and edema which can still remain following therapy-triggered cell death, 
contributing to the apparent tumor mass (141). The full clearance of the dead tissues is likely to 
require more than five days, as indicated from Fig. 8, 9, and 10 where we saw the presence of 
scar tissues at the site of tumor implantation, approximately 4 months after discontinuing CCP 
treatment. Thus to validate the role of the recruited NK cells in the 5-day CCP treatment-evoked 
apoptosis of GBM cells, we observed in parallel, a population of CD68
high
 (GBM cells) and 
activated caspase-3(-) (Act. Cspse3(-)) cells (in the blue circle) in the Vehicle-treated GBM mice 
(Fig. 27 Fi and G), but the tumors in the CCP-treated mice harbored mainly CD68
high
, Act. 
Cspse3(+) cells (in the red ellipse) with a very small number of CD68
high
 but Act. Cspse3(-) cells 
(in the blue circle)  (Fig. 27 Fii and G) (29, 58).  This CCP-evoked 1187% increase in Act. 
Cspse3(+), CD68
high
 cells was reduced to 343% in the CCP+NK1.1Ab-treated GBM mice (Fig. 
27 Fiii,iv, and G). Thus, the difference in the increase in Act. Cspse3(+) cells between CCP and 
CCP+NK1.1Ab (1187%-343% = 844%) was likely due to the NK cells which were recruited into 
the GBM. By contrast, the CD68
low
, Act. Cspse3(-) cells (presumably the TAM) remained 
unaltered in all three groups, signifying that CCP-associated CC does not affect the viability of 




Fig. 27. The elimination of intra-GBM recruitment of activated NK cells partially reverses the 
CCP-evoked elimination of CD133(+) GBM stem cells and CD68
high
 GBM cells. The GBM tumor in 
each mouse was cut into two parts and processed for IHC and Flow Cytometry (please see 'methods and 
materials' for more details). (A-B) IHC: the Vehicle-treated mouse GBM tumors harbored a considerable 
number of CD133(+) GBM stem cells (red) (A first row). Compared to the Vehicle-treated group, the 
CD133(+) fluorescence showed a 72% reduction in the CCP-treated group (*p = 6.5x10-3 CCP versus 
Vehicle) (A, second row and B) but a 41% reduction in the CCP+NK1.1-treated GBM mice (A third row 
and B) ((∆ p < 0.02, CCP+NK1.1 versus CCP; **p = 0.03, CCP+NK1.1 versus Vehicle).  (Scale bar: 
47.62 µm).  (C-F) Flow Cytometry: compared to the Vehicle-treated, the CD133(+) GBM stem cells (C, 
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top, red circle) were suppressed by 81% in the CCP-treated group (C middle and CD133 IF shown in D) 
(*p < 0.05, CCP versus Vehicle) and by 32% in the CCP+NK1.1 group (C, bottom, and D) (∆ p < 0.03, 
CCP+NK1.1 versus CCP; **p = 3.0x10-3, CCP+NK1.1 versus Vehicle).  (E) The fluorescence profiles of 
the CD133(+) GBM stem cells in the Vehicle, CCP, and CCP+NK1.1 samples. (F-H)  The dispersed cells 
from the GBM tumors were also double-stained with CD68, and active-caspase-3 (Act. Cspse 3). (F i) In 
the Vehicle-treated group, two discrete populations of CD68(+) but Cspse3(-) cells were identified 
(Lower Right, LR). The larger population (shown within the blue circle) was CD68high (most likely GBM 
cells) whereas a smaller population (shown within the green circle) was CD68low (likely be the TAM) (29, 
42, 58). A very small population of CD68(+), Act. Cspse3(+) (double positive) cells was seen in the upper 
right (UR) quadrant (within the red ellipse).  (F ii) In the CCP-treated group, CD68high cells showed an 
1187% increase in Act. Cspse 3 IF (red ellipse in the UR quadrant) with respect to Vehicle, along with the 
almost disappearance of the CD68high but Cspse3(-) population (in the blue circle) in the LR quadrant (*p 
= 0.036, CCP versus Vehicle) (F ii and G). The Act. Cspse 3 IF increased by 343% in the CCP+NK1.1 
samples, along with the reemergence of some CD68hgh but Act. Cspse 3(-) cells (in the blue circle) in the 
LR quadrant (F iii and G) (∆ p < 0.04, CCP versus CCP+NK1.1; **p=3.1x10-3, CCP+NK1.1 versus 
Vehicle).  (F iv) Fluorescence profiles for Act.Cspse 3. The CD68 fluorescence in CD68low cells (TAM) 
was not significantly different in the three groups (H).  The graphs represent data (mean ± S.E.M.) 






Fig. 28. Peripheral injection of the GBM mice with a NK cell-neutralizing antibody NK1.1 partially 
reverses the CCP-mediated elimination of SOX2(+) GBM stem cells. (A) GBM brain sections from 
the three groups parallel to the ones used for IHC in Fig. 27, were single-stained with antibody against 
SOX2. The sections from the Vehicle-treated mice demonstrated considerable number of SOX2(+) GBM 
stem cells (A first row). In comparison, the sections from CCP-treated GBM mice exhibited a 79% 
suppression of SOX2(+) cells (*p = 8.6x10-3, CCP versus Vehicle) (A, second row, and B).  While, the 
CCP-evoked suppression of SOX2(+) GBM stem cells was only 54% in the samples from CCP+NK1.1 
treated group ((∆ p = 0.015, CCP+NK1.1 versus CCP ;**p = 0.025, CCP+NK1.1 versus Vehicle) (A, 
third row, and B). Three random sections per mouse were used for analysis and the graphs represent data 
(mean ± S.E.M.) obtained from Vehicle (n=4), CCP (n=4), and CCP+NK1.1 (n=3). (Scale bar: 47.62 µm) 
(73). 
 
























     








Fig. 29. The abrogation of intra-GBM recruitment of activated NK cells by peripheral injection 
with IL12 Ab partially eliminated the M1-type phenotype of  the GBM TAM.  GBM Brain sections 
parallel to the dispersed cells used in Fig. 20 from the Vehicle, CCP and CCP+IL12Ab-treated GBM 
mice were used to assess and quantify the expression of iNOS (M1 marker) on tumor associated microglia 
(Iba1(+)/RM0029-11H3(-)) and macrophages (Iba1(+)/RM0029-11H3(+)) upon CCP and CCP+IL12Ab 
treatment. (A) The GBM sections from the Vehicle-treated mice harbored mostly tumor-associated 
microglia but few macrophages (first row) both of which expressed low levels of iNOS. The CCP (second 
row) treatment of the GBM mice displayed abundant number of both iNOS+ intra-GBM recruited tumor-
associated macrophages and resident microglia. The CCP+IL12Ab-treated (third row) GBM mice also 
showed large number of both intra-GBM recruited tumor-associated macrophages and resident microglia, 
but with intermediate expression of iNOS (with respect to the other two groups). (B) CCP-treatment 
caused a 474% increase in the intensity of iNOS (fluorescence intensity normalized to the number of 
cells) in microglia (*p = 8.8x10-6 Vehicle versus CCP), while CCP+IL12Ab-treatment triggered a 242% 
increase in iNOS intensity in microglia with respect to the Vehicle (**p = 1.2x10-3 Vehicle versus 
CCP+IL12Ab) (∆p = 4.1x10-3 CCP versus CCP+IL12Ab). CCP-treatment induced a 498% increase in 
iNOS intensity in the macrophages (*p = 5.4x10-5 Vehicle versus CCP), whereas CCP+IL12Ab-treatment 
caused a 250% increase in iNOS staining intensity of macrophages with respect to the Vehicle (**p = 
5.4x10-5 Vehicle versus CCP+IL12Ab) (∆ p = 3.5x10-4 CCP versus CCP+IL12Ab). Four sections per 
mouse were used for analysis and the graphs represent mean ± S.E.M. acquired from Vehicle (n=3), CCP 
(n=3), and CCP+IL12Ab (n=3) groups (Scale bar:  47.62 µm.) (73). 
 
3.18  In the CCP-treated GBM mice, the M1-like polarity of both macrophages and 
microglia in the GBM tumor is partially eliminated upon peripheral injection of the IL12 
antibody. Complete abolition of NK cell recruitment via peripheral treatment of NK1.1 antibody 
causes partial reversal of M2M1 repolarization (Fig. 24-26). Since data presented in Fig. 20 
show that this NK cell recruitment into the GBM tumor is contingent upon peripheral IL12-
mediated signaling, and because it known that NK cells can cause M1 polarization, we would 
expect that IL12Ab injection would partly abrogate the magnitude of M1 phenotype of both 
macrophages and microglia harbored within the GBM tumor (115, 117, 127, 128). 
Corroboratively, the CCP-evoked stimulation in iNOS in the Iba1(+) macrophages (RM0029-
H3(+), Iba1(+)) (498%) and the microglia (RM0029-H3(-), Iba1(+)) (474%) was partially 
abrogated in the IL12Ab-treated tumors (Fig. 29 A, B) (29). With respect to the Vehicle-treated 
GBM mice, the CCP+IL12Ab-treated GBM mice demonstrated a 250% increase in iNOS in the 
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macrophages and a 242% increase in iNOS in the microglia (Fig. 29 A, B). Consequently, the 
differences (498%-250% = 248% and (474-242 = 232%, respectively for macrophages and 
microglia) were due to the recruited NK cells within the GBM. 
 Our studies demonstrated CCP-induced recruitment of M1 macrophages (Fig. 29, 21) and 
activated NK cells (Fig. 19), which join the resident M1-polarized microglia to promote GBM 
elimination. We wanted to further analyze the mechanism responsible for the influx of these 
tumoricidal immune cells into the GBM mass. The study presented in Fig. 20 show that NK cell 
recruitment into the GBM tumor depends on peripheral IL12-mediated signaling.  The principal 
source of IL12 was likely to be the M1 macrophages, which themselves were also recruited into 
the GBM (Fig. 21, 24 and 26). The most tempting choice seemed to be the M1 microglia-
derived IL12 (Fig. 24, 26), which could exit the brain, activate NK cells that would in turn 
activate M1 macrophages and eventually both of these immune cells get recruited into the GBM 
brain. But, since M1 microglia-derived IL12 is a cytokine and not a chemokine, it is highly 
improbable that it can cross the BBB to cause long distance chemotactic attraction of the 
peripheral immune cells into the GBM brain. By investigating the available literature, a 
promising candidate that had the potential to cause this recruitment appeared to be the 
chemokine monocyte chemotactic protein-1 (MCP-1) (aka CCL2) , possibly derived from the 
CCP-triggered M1-microglial cells. 
3.19 CCP treatment causes a dramatic IL12-independent induction of monocyte 
chemotactic protein-1 (MCP-1) expression in the TAM. Earlier studies have established the 
chemokine MCP-1 as a phenotypic marker of M1 macrophages and microglia and its higher 
expression has been associated with tumor elimination (75, 81, 136, 142-144).  Furthermore, 
68 
 
MCP-1 is known to penetrate the BBB to shuttle from the brain into the peripheral system and 
can also trigger recruitment of immune cells such as M1-like macrophages and activated NK 
cells (79-81, 134, 136). CCP treatment in both absence as well as presence of peripheral IL12Ab 
injection caused a dramatic induction of both tumor-associated microglia and macrophage-
associated MCP-1 in the GBM brain (Fig. 30, 21). We have shown earlier that CC-treatment of 
tumor-bearing mice causes an induction of activated, p65 NF-kB in Iba1(+) TAM (Fig. 15) (42, 
72). Moreover, p65 NF-kB has been shown to induce MCP-1 expression (145, 146), which could 
possibly be the mechanism of CCP-mediated induction of MCP-1 in the TAM of these GBM 
mice. 
 Based on this information, we hypothesize that CCP-triggered MCP-1 release from M1 
microglia initiates a cascade of events to cause M1 macrophage activation and subsequent intra-
tumor recruitment of these cells. Concurrently, IL12 released from these M1 macrophages 
triggers NK cell activation and MCP-1-induced influx of activated NK cells into the GBM brain. 
These recruited NK cells within the GBM further augment the 'M1-ness' of these microglia and 
macrophages (TAM) to synergistically cause elimination of GBM and GBM stem cells (Fig. 31). 
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Fig. 30.  CCP treatment causes a dramatic induction of MCP-1 in the Iba1(+) TAM. GBM brain 
sections parallel to the ones used in Fig. 29, from the three groups (Vehicle, CCP and CCP+IL12Ab) 
were immunostained to evaluate the expression of MCP-1 on the Iba1(+) TAM. (A) The TAM of the 
Vehicle-treated GBM mice (first row) expressed very little MCP-1, whereas the data from both the CCP 
(second row) and CCP+IL12Ab-treated (third row) showed that the TAM strongly express MCP-1. (B) 
CCP-treatment triggered a 374% boost in the MCP-1 expression in the microglia (*p = 2.6 x 10-5 Vehicle 
versus CCP), whereas CCP+IL12Ab group showed 323% increase in MCP-1 intensity (**p = 6.5x10-6 
Vehicle versus CCP+IL12Ab). No significant difference was observed between the CCP and 
CCP+IL12Ab groups. Four sections per mouse were used for analysis and the graph represent data (mean 
± S.E.M., fluorescence intensity normalized to the number of cells) obtained from Vehicle (n=3), CCP 






Fig. 31. Possible signaling pathways involved in the CCP-mediated M2M1 TAM repolarization, 
intra-tumor recruitment of M1-type macrophages and activated NK cells.  CCP initiates a complete 
signaling cascade by inhibiting active STAT3 in the tumor-associated M2-like microglia (147). This 
releases STAT1 from the inhibitory effects of STAT3 (115). Induced P-STAT1 triggers the synthesis of 
iNOS, IL12, thereby activating and proliferating M1-type microglia (75, 142). MCP-1 released by GBM-
associated M1-type TAM compromises the blood-brain barrier (BBB), exits into the peripheral system, 
activates macrophages to their M1-type phenotype by binding to their receptor (CCR2), and recruits them 
into the GBM brain (56, 74, 77, 79, 81, 134).  Concurrently, these M1-type macrophages in blood elicit 
STAT1-mediated IL12 synthesis and release (100). The released IL12 binds to IL12 receptor (IL12R) on 
the peripheral NK cells, thereby activating these cells and causing interferon-gamma (IFNγ) release (71). 
The released IFNγ causes receptor-mediated inhibition of STAT3 in the macrophages (116, 118, 148), 
which further amplifies the M1 macrophages via activation of STAT1(117, 149) to cause more IL12 
release (115). These sequence of events further stabilizes the M1 phenotype and the activation of NK 
cells. Concomitantly, brain-released MCP-1 also binds to CCR2 on IL12-activated NK cells (150) and 
causes recruitment of these cells into the GBM brain (81). Once in the brain, the activated NK cells 




activated NK cells also kill resting microglia, thus enriching the M1-type microglia in the TAM (151). 
Simultaneously, the M1-type macrophages and microglia within the GBM brain induce iNOS-mediated 
release of nitric oxide (NO) (69, 134), which (in addition to other path-ways) eradicates GBM tumor cells 
and GBM stem cells (73).      
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Chapter 4: Discussion 
As evidenced by the plethora of available scientific reports, the plant-derived dietary polyphenol 
CC has generated immense interest in the recent years (3, 17, 18, 26, 36, 52, 140, 152-156). 
Multiple in vitro and in vivo studies for a variety of diseases have established CC's effectiveness 
against cancer and its significance in the health sciences (153, 154, 156, 157). However, the lack 
of significant outcomes in human clinical trials has considerably dampened interest in 
considering CC as a future therapeutic agent (152, 155, 158-161).  Our group has persistently 
maintained the notion that such failures are due to CC’s low bioavailability, hydrophobicity and 
lack of stability in vivo, all of which can be circumvented by designing delivery systems. This 
could reinstate CC's importance as a promising therapeutic agent (28, 29, 33, 41, 58, 72). Instead 
of treating cancer cells with toxic agents or radioisotopes (162-165), suitable delivery methods of 
CC would overcome its low bioavailability and also could potentially stimulate the body's own 
immune system to fight the residual cancer cells (17, 18, 26, 42, 52, 72, 166-170). 
 With these aims in our mind we employed two different strategies, (i) delivering CC in a 
commercially available PC-complexed form that is already consumed as a supplement (46, 96),  
(ii) delivering CC linked to a GBM-selective antibody (29, 42). The first strategy involving 
usage of CCP was expected to increase the stability and bioavailablity of CC in vivo so that the 
dose of CC would be adequate to eliminate GBM efficiently. In the second strategy, we linked 
curcumin to a CD68 antibody through an ester bond that would make the CC-CD68Ab adduct 
highly bioavailable, water soluble, relatively stable and cleavable by intracellular esterases after 
entering target cells (28, 29). This strategy was highly efficient in vitro. We expected that once 
delivered in vivo, this adduct would target CC mainly to the CD68
high
 GBM cells and also the 
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TAM that are CD68
low
 (Fig. 3, 18 and 27) (29, 58, 73). Endocytosis-mediated entry of CC-
CD68Ab molecules would trigger the release of CC within the GBM cells, causing them to 
undergo cell death (29).  
 CC is known to eliminate a wide array of tumors by modulating a variety of cell signaling 
processes, while being protective to normal untransformed cells (101, 171). We have previously 
shown that CC can eliminate GL261 cells in vitro by chiefly inhibiting NF-kB signaling in these 
cells (29).  In contrast, in the tumor-associated microglia/macrophages, activation and induction 
of the p65 NF-kB is known to cause inhibition of p300-HAT, which in turn activates and 
stabilizes the tumor suppressor protein p53 (58).  We have shown that in vitro CC treatment 
activates and stabilizes p53 in GL261 cells, which drives caspase-3-triggered apoptosis in these 
cells (58). However, these cytotoxic effects toward the tumor cells were observed at supra-IC50 
concentration of CC. Intriguingly, pharmacokinetic analyses in rats revealed that the 
concentration of CCP-associated CC after oral delivery was far below the IC50 of CC for the 
GL261 cells (Fig. 5) (40, 44-46). Even though i.p. delivery was expected to yield a higher 
concentration of CC in the plasma than oral delivery, our pharmacokinetic studies with a 
liposomal version of CC showed that the plasma concentration of CC in mice was still much 
lower than the IC50 of CC for cultured GL261 cells (Fig. 5) (58).  Furthermore, although the 
CC-CD68Ab adduct gets selectively concentrated in the GBM cells, it is expected that the intra-
brain concentration of CC-CD68Ab-associated CC would be quite low.  However, as shown by 
our data, this adduct also causes repolarization of the GBM-associated immune cells (35, 45). 
Thus, it was highly likely that the in vivo mechanism of CC-mediated GBM elimination involves 
CC's indirect tumoricidal effect through the immune cells. Additionally, other studies have 
shown that CC-treatment can influence tumor-associated immune cells by triggering 
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repolarization of M2-like tumor-associated macrophages and activation of tumoricidal T cells to 
cause tumor elimination (17-19, 26, 50-52). Based on such observations, we hypothesized that 
CC (CCP and CC-CD68Ab) treatment-mediated rescue of the GL261-implanted GBM mice 
involves the immunotherapeutic activation of the GBM-associated immune cells (18, 26, 50, 58, 
72).  
 The most abundant immune cell type in the GBM mass (30-40% of the GBM mass) are 
are the GBM-associated microglial/macrophage cells (TAM) which are known to be polarized to 
the pro-tumor M2-like phenotype (113). Furthermore, some targeted CC-CD68Ab molecules 
would also be taken up by the CD68
low
 TAM.  Such effects of CC (CCP and CC-CD68Ab) on 
TAM was likely to be the chief trigger to cause elimination of the GBM tumor cells (128).  
These CC treatments could involve repolarization of the tumor-promoting M2-like TAM 
population to the tumoricidal M1-like phenotype (18, 50, 53, 59, 60, 62). Thus, we first studied if 
the TAM were affected by CC treatment, by employing  IHC and flow cytometry to identify and 
quantify the expression of ARG1 (M2 marker) or iNOS (M1 marker) in the Iba1(+) TAM (73). 
This was not achievable by Western blotting or ELISA-based assays, because ARG1 and iNOS 
are ubiquitous enzymes expressed by other cell types in the GBM tumor and scar tissue that are 
not Iba1(+) and would yield ARG1 and iNOS profiles that may not be associated to the TAM. 
The overall repolarization was validated by both IHC and flow cytometry showing that in the 
CC-treated and rescued mice, there was a 154-206% increase in iNOS fluorescence along with a 




 Since Iba1 is the signature of activated microglia/macrophages (105, 108), the results 
indicate that in the CC-treated and rescued mice, the tumor-associated ARG1
high
, Iba1(+) M2-
like TAM population is suppressed while a different population of  iNOS
high
, Iba1(+) M1-like 
TAM is activated.  In addition to the activation of intra-GBM M0-like microglia, another source 
of this new M1-like TAM population could be the intra-GBM recruited M1-type macrophages, 
which are also identified by Iba1 staining  (72, 73, 81, 172). This hypothesis was confirmed by 
the short-term CCP-treatment studies. We found that indeed 50-60% of the TAM within the 




/Iba1(+) cells between the Vehicle-treated and CC-treated and rescued 
groups remained unaltered, indicating that the proportion of M2-like TAMs (Vehicle group) was 
approximately equivalent to the proportion of M1-like TAMs (CC-treated and rescued) (Fig. 12). 
This was further verified from the short-term CCP-treatment studies, when CD68
low
 cells (marks 
both M1 and M2-like TAM) remained unaltered despite CCP or CCP+NK1.1Ab treatment (Fig. 
27). This demonstrates that CC does not affect the viability of the TAM, rather it repolarizes the 
M2-like TAM milieu to the tumoricidal M1-like population (Fig. 27). Thus, CC-evoked tumor 
elimination (Fig. 9, 10 and 27) most likely involves suppression of the tumor-promoting and 
immunosuppressive M2-like microglia along with concomitant activation of M1-like microglia 
and recruitment of tumorcidal M1-like peripheral macrophages (Fig. 21, 29, 30 and 31). The 
observed suppression of activated STAT3 (Fig. 13 and 22) and simultaneous induction of 
activated STAT1 (Fig. 14 and 23) is likely to play a central role in the CCP-mediated 
suppression of activated STAT3
high
 M2-like TAM and concurrent induction of STAT1
high
 M1-
like TAM. This proposed molecular mechanism of the CC-evoked switch in M2 to M1 
polarization was based on previous studies performed mainly on peripheral macrophages where 
76 
 
it has been shown that the non-classical M2 activation of tumor-associated macrophages 
involved the induction of the transcription factor STAT3, which causes induction of ARG1 
expression and blocks STAT1 activation (100, 173). Interestingly, CC has been reported to cause 
inhibition of STAT3 in tumor-associated macrophages from in vitro and in vivo experiments (50, 
147). Similarly,  in our studies the CCP-treated and rescued mice also showed a sharp inhibition 
of activated-STAT3 (P-Y
705
-STAT3) in the TAM (Fig. 13). Activated STAT3 is known to 
induce the expression of immunosuppressive factors, such as IL10 (122, 134), and IL10 in turn is 
known to inhibit IFNγ-mediated STAT1 activation (115).  It was anticipated that in the GBM 
mice, CC treatment would be associated with suppression of activated STAT3 and abrogation of 
the STAT3-IL10-induced inhibition of activated STAT1. We observed an inhibition of IL10 in 
the TAM of the CC-treated and rescued mice (Fig. 16). Therefore, based on our data and 
previous studies in tumor-associated macrophages, it is likely that CC treatment of the GBM 
mice would cause an enhancement of activated STAT1 (P-Tyr
701
-STAT1) in the 'resting' (M0-
like) microglia causing activation and proliferation of the tumorcidal M1-like phenotype (Fig. 21 
and 27). Corroboratively, we observed a sharp augmentation in activated STAT1 (P-Tyr
701
-
STAT1) in the scar tissue associated- Iba1(+) TAM of the CC-treated and rescued brains (Fig. 
14).  
Simultaneous to induction of activated STAT1, we also noticed a conspicuous increase in 
activated NF-kB (P-Ser
276
-p65) in the Iba1(+) scar tissue TAM (Fig. 15). Activation of TAM-
associated, heterodimeric p50/pp65 NF-kB is quantified by increment in P-Ser
276
-p65, which is 
associated with the activation of M1-type macrophages (72, 174). Additionally, it has been 
demonstrated that tumor-associated macrophages exhibit alternative macrophage activation (M2 





-p65 in the Iba1(+) TAM of the CC-treated and rescued mice brains 
(Fig.15) suggested that the CC-treatment inhibited the p50 homodimer signaling in the TAM and 
induced the activation of the p50/p65 NF-kB, which is associated with the classical activation 
(M1) phenotype. A prototypic STAT1-sensitive sequence (e.g. the iNOS gene and IL12 gene) 
also houses a NF-kB-specific enhancer sequence in its promoter and causes a synergism between 
STAT1 and p65 NF-kB in the regulation of a genes linked to inflammation (120, 121). So, CC-
triggered, simultaneous induction of activated STAT1 and activated p65 NF-kB could be the 
likely reason for the increased appearance of iNOS
high
 and IL12 
high 
(M1 polarized) Iba1(+) TAM 
in the scar tissue of the CC-treated and rescued mice (Fig. 11, 12 and 16).  
It has been demonstrated that  IL12 (expressed by M1-like TAM in this context) (Fig. 16) 
is a potent activator of  NK cells and these activated NK cells are recruited into peripheral 
tumors and into the brain under various conditions (69, 126, 151).  So, we  next asked if CCP 
treatment triggers intra-GBM recruitment of NK cells. We observed that the scar tissue from the 
CCP-treated and rescued mice, but not the GBM tumor in the Vehicle-treated mice, harbored a 
large number of activated NK cells (Fig. 17).  
Although the results from our long-term rescue data demonstrate that following 
appropriate delivery, CC in both CCP and CC-CD68Ab brings about tumor remission in 50-60% 
of mice harboring established brain tumors, it was not clear why the remaining 40-50% mice 
were not rescued (Fig. 8). A likely reason was that the immune system of each mouse was 
discretely responsive to long-term CC treatment. So, our next aim was two-fold. Firstly, we 
asked if these NK cells in any way might influence the observed CCP-evoked repolarization of  
TAM and elimination of GBM and GBM stem cells. Our second question was if M2M1 TAM 
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repolarization in the GBM was influenced by intra-GBM NK cell recruitment. We were also 
interested in exploring the mechanisms of TAM repolarization and intra-GBM recruitment of 
activated NK cells. 
  Concomitant with the intra-GBM NK cell recruitment, we found that five days of CCP 
treatment was also adequate to cause a permanent M2M1 TAM repolarization. Interestingly, 
we found that these recruited NK cells were partially responsible for the CCP-evoked 
suppression of the M2-type markers, such as P-STAT3 (by 27.5%), IL10 (by 27%), and ARG1 
(by 20%) in the TAM. Simultaneously, these NK cells were also partly responsible for the CCP-
evoked marked increase in the tumoricidal M1-type markers, such as P-STAT1 (by 986%) and 
IL12 (by 376%) in the TAM (73). The consequent IL12-evoked NK cell activation may amplify 
and prolong the M1 polarization of  the GBM TAM through IFNγ released by the activated NK 
cells (71, 72), thereby causing a 204% boost in iNOS expression, which would catalyze the 
formation of cytotoxic NO inside the GBM (Fig. 19, 22, 23, and 24) (151). Finally, the recruited 
NK cells are also responsible for 49% of the CCP-evoked inhibition of CD133(+) GBM stem 
cells and 844% enhancement in active caspase-3 in the CD68
high
 GBM cells (Fig. 27). In view of 
earlier observations that GBM cells and GBM stem cells can trigger STAT3-evoked induction of 
immunosuppressive M2 microglia/macrophages (134, 175), the anti-STAT3 activity of CC along 
with the anti-GBM and anti-GBM-stem-cell activities of NK cells are likely to be central to the 
observed GBM remission in the CCP-treated mice (30, 50, 126, 176) (Fig. 8, 9 and 10).   
 Our data also show the occurrence of NK-cell-independent CCP-triggered recruitment of 
M1-type macrophages into the GBM tumor microenvironment. About 50-60% of TAMs within 
the GBM tumor mass were comprised of these recruited M1-like macrophages (Fig. 21). This 
79 
 
may partially account for the dramatic M2M1 switch in the TAM milieu and explain the 
induction of discrete populations of M1-like TAM in the CCP-treated and rescued mice (Fig. 
12). With the information gathered from our studies it was essential for us to delve into a 
possible mechanism of CCP-mediated intra-GBM recruitment of M1-macrophages and activated 
NK cells. It is well-known that the chemokine MCP-1 is a marker of M1-like 
microglia/macrophages (123, 150). Immunostaining analysis of GBM brains from the 5-day CCP 
treatment showed a NK cell-independent, CCP-evoked induction of MCP-1 within the GBM 
TAM (Fig. 30). MCP-1 is known to permeate the BBB and exit into the blood stream. Moreover, 
it is known to bind to its receptor (CCR2) on M1-type macrophages and activated NK cells, and 
recruit them into the site of its expression like the tumors or inflamed brain (56, 74, 79, 81). 
Interestingly, high expression of MCP-1 is known to cause tumor destruction via recruitment of 
peripheral NK cells and macrophages. Additionally, elimination of MCP-1 is known to cause 
abrogation of the recruitment of these immune cells into the brain or tumor sites (56, 81, 134, 
143, 177). Furthermore, MCP-1 is also known to bind to CCR2 expressed by activated NK cells 
and recruit them into the tumor site (81, 134). Based on such evidence, we hypothesize that the 
CCP-induced chemokine MCP-1 (produced by M1-like GBM-associated microglia) exits the 
brain, triggers a cascade of events to first activate M1-type macrophages, which signal through 
IL12 to activate the NK cells, which turn get attracted by MCP-1 into the GBM mass. MCP-1 
thus recruits both M1-macrophages and activated NK cells into the GBM tumor.  Once inside the 
GBM, the NK cells would stabilize the M1 phenotype of the GBM TAM. It is expected that the 
synergistic action of these immune cell types would trigger efficient GBM elimination, as seen 
from our results (Fig. 31).  
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 CC is known to be a potent anti-inflammatory agent (178).  However, in the context of 
CC-treated of GBM mice, GBM-associated immune cells (M1-like TAM and NK cells) are most 
likely eliciting inflammation-mediated GBM elimination. Thus, this study explores a paradoxical 
and novel role of CC as an immunotherapeutic agent whose pro-inflammatory (anti-tumor) role 
could arise from the highly immunosuppressive environment present within the GBM mass (17, 
18, 26, 50).  Nevertheless, further pharmacokinetic analyses need to be undertaken to reveal the 
effective concentrations of CC required to cause (i) permanent M2→M1 repolarization of TAM 
(ii) intra-GBM recruitment of NK cells. In addition, the direct role of CC in causing the 
activation phenotype of the tumor-associated immune cells needs to further studied. These data 
would provide useful information about the direct concentration-dependent CC-mediated 
activation of these tumor-associated immune cells to their anti-tumor phenotype. This will be 
particularly important as the effective concentrations of CC required for immuno-stimulation 
could be translatable to potential clinical application in GBM patients. 
Lately T cell-based conventional cancer immunotherapeutic techniques like chimeric 
antigen receptor (CAR) T cell treatment and regulators of T-cell activation (checkpoint 
inhibitors) have come into prominence but they are partially successful because of limitations 
and side effects in the patients. These include flu-like symptoms like fever, dizziness, nausea or 
vomiting, muscle or joint aches, fatigue, trouble in breathing etc. Other symptoms include 
swelling and weight gain from fluid retention, diarrhea, and risk of infection to name a few (179, 
180). Although immunotherapy investigations targeting T cells had resulted in technically 
successful treatment protocols for most cancers, only a small fraction of cancer patients respond 
to these treatments (181, 182). Additionally, cancer immunotherapy poses unique complexities in 
the context of GBM therapy because of immunosuppression caused by the GBM cells, the 
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presence of the BBB, occurrence of a low number of T-cells in the brain, and deficiency of a 
lymphatic system which limits the entry of immune cells to enter the CNS etc (16, 23). Thus, our 
studies with CC provide a unique and highly effective immunotherapeutic approach, which can 
circumvent the above-discussed limitations of conventional GBM immunotherapy. Additionally, 
there has been an increase in interest among scientists to study the relatively less-known and 
unexploited innate immune cells like NK cells, macrophages and microglia as potential targets 
for oncoimmunotherapy (183). As shown by our studies, CC is a promising immunotherapeutic 
agent for GBM tumors (73).  
Our studies using another CC formulation (TriCurin) on other cancer models like mouse 
cervical tumors and head and neck tumors show that CC can be a potential immunotherapeutic 
agent against solid tumors (33, 34, 58, 72). We have shown that it can activate M1-like 
macrophages, NK cells and cytotoxic T lymphocytes (CTL) to cause tumor elimination (33, 34, 
58, 72). Furthermore, it has been shown in other peripheral cancers that triggering the activation 
and intra-tumor recruitment of tumoricidal immune cells like M1-like macrophages, NK cells 
and CTL confers the advantage of tumor immuosurveillance. This can delay tumor progression 
or trigger tumor elimination (91, 183-185). In addition, CC has been shown to have 
immunotherapeutic potential in other solid tumors like melanoma and breast cancer (17, 18, 26, 
50). In light of information presented here, this CC-mediated strategy could eventually become 
an effective general approach for new-age cancer immunotherapy against a wide array of tumors 
(58, 72).  CCP is therefore a safe and promising agent that can boost the innate immune system 
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